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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
 
1.1. OBJECTIVES OF REVIEW 
 
This review will aim to provide an overview of calcium homeostasis and its 
estimation with particular emphasis on: 
• Ionised calcium and its measurement 
• Total calcium and its measurement 
• Derivation of corrected calcium  
• Rationale for adjusted calcium including the effect of serum albumin and 
calcium methodologies in the estimation of calcium status 
 
1.2. SEARCH CRITERIA 
 
The following search criteria were used on Pubmed as the following MeSH terms: 
adjusted or corrected calcium and serum albumin. References in written papers were 
also used as part of the literature search.  
 




Calcium is a divalent cation with multiple roles, including a structural role in bone 
and various metabolic roles. These include blood coagulation, muscle contraction, cell 
membrane potential, cell permeability as well as hormone secretion, action and 
signalling (1). Most total body calcium (99%) is contained in the skeleton, where it 
contributes to its mechanical properties and provides a reservoir for calcium in the 
extracellular fluid (ECF). The makeup of the remaining 1% is intracellular (0.8%) and 
extracellular (0.2%). Serum calcium is present in 3 physiological states: protein bound 
(30-55%), complexed (5-15%) and free (50%) calcium fractions. Approximately 90% 
protein bound calcium is attached primarily to albumin with the remaining 10% to 
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globulins. Calcium bound to small organic anions (i.e. citrate, bicarbonate, sulfate, 
phosphate and lactate) constitutes complexed calcium. 
 
The complexed and free fractions of the serum total calcium (tCa) concentration 
constitute the diffusible fraction. It is also known as the ultra-filterable calcium as it 
diffuses through physiological membranes. The protein-bound calcium is the non-
diffusible fraction. Each albumin molecule consists of approximately thirty binding 
sites with only about 10 to 15% being utilized under normal conditions for binding 
ligands. The free calcium is the biologically active form and is tightly regulated to 
maintain a narrow physiological range. Excess of calcium in the blood results in a 
relative increase of the protein-bound fraction to maintain a constant free calcium 
concentration, and vice versa. All calcium in the human body exists in the ionised 
form. Non-ionised calcium is a flammable metal and not present in any body tissue 
(2). However, conventionally, the term “ionised calcium” is used to refer to the 
biologically active free calcium fraction.  
 
The protein-bound pool acts as reservoir for ionised calcium (iCa). Any transient drop 
in the free fraction is compensated for by release of calcium ions from the calcium 
binding sites on the albumin molecule (2). This constitutes the short-term control of 
iCa. Various factors influence the amount of bound or complexed calcium. These 
include abnormalities in plasma protein concentration; pH changes; changes in ion 
concentration (i.e. sodium, magnesium and phosphate); and the presence of chelators 
such as lactate and citrate. Additionally, variations in the concentration of free fatty 
acids that bind to albumin can affect the ionised and/or the complexed portion (3).  
 
B. Variations in Calcium Homeostasis 
 
Calcium control is tightly regulated by parathyroid hormone (PTH) and 1,25-
dihydroxyvitamin D (1,25(OH)2D) to maintain a narrow physiological range of iCa. 
Together they control the resorption of calcium from bone, dietary calcium absorption 
from the intestine and reabsorption of calcium from the renal tubules (4). Calcitonin, 
to a lesser extent, plays a role in calcium homeostasis, particularly during 
hypercalcaemia. Its principal role is to inhibit osteoclast mediated bone resorption to 
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maintain normal iCa levels. Hormonal regulation of calcium homeostasis constitutes 
the long-term control of iCa.  
 
Various hypotheses exist regarding the regulation of tCa and iCa. Over and above 
hormonal influences, calcium levels seem to show variability related to age. This has 
been well demonstrated in the elderly, post-menopausal women and neonates. 
Homeostatic control of physiological systems is known to decrease with increasing 
age (4). The decline in calcium control is further confounded by increased variability 
of serum iCa, which may be attributed to variations in circadian rhythm; nutritional 
status; physiological response to exercise; hormonal influences; serum magnesium 
levels and the renin-aldosterone system (4). In a large epidemiological study, Watson 
et al not only demonstrated variability in iCa with age but also with gender. This 
variability occurred earlier in women than in men (4).  
 
Serum tCa has been demonstrated to decline with age (5). This is attributed to an age-
related decline in serum albumin concentration. In addition, calcium absorption 
declines with age, despite an age related increase in PTH levels. Vitamin D deficiency 
also contributes to decreased calcium absorption, common in the elderly. In contrast, 
menopause is associated with increased tCa but does not affect iCa and serum 
albumin concentration (6). The elevation in tCa is likely due to an increase in the 
complexed or protein-bound calcium fraction. Increased bone resorption secondary to 
stimulated PTH secretion is unlikely to account for this increase as iCa remains 
unchanged. Nordin et al demonstrated similar findings in post-menopausal women 
(7). The increased tCa was accounted for by an elevation in the complexed fraction, as 
this was associated with an increased anion gap and bicarbonate concentrations. There 
were no changes in 1,25(OH)2D and PTH levels.  
 
A complex process regulates calcium homeostasis in pregnancy, in the foetus and the 
neonate. This involves endocrine and non-endocrine mechanisms. The latter include 
dietary calcium and phosphate balance; intestinal calcium secretion; kidney 
maturation; and acid-base regulation (8). Foetal skeletal development imposes high 
demands on calcium requirements during pregnancy. This is met by an elevation in 
maternal PTH secretion secondary to parathyroid gland hyperplasia. Active vitamin D 
synthesis is also increased leading to increased absorption of calcium (9). Despite 
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these changes, maternal tCa levels decline to a nadir at 28 to 32 weeks, largely due to 
a mild hypoalbuminaemia. The iCa levels, however are maintained in the 
physiological range throughout pregnancy. The abrupt removal of the maternal 
calcium supply at birth result in alterations in iCa in neonates. As such, adjustments 
from high to normal calcium levels are observed. Subsequently, an early 
physiological hypocalcaemia occurring within the first 48 hours has been described in 
infants born before 37 weeks gestation; in perinatal asphyxia; and those born from 
diabetic mothers (8).  
 
The observations above highlight the importance of determining the calcium fraction 
that is not affected by this variability. This will determine the choice of the calcium 
measurement that will be a more reliable estimate of calcium status. Patient groups 
affected by variation in tCa will benefit from measurement of iCa to reliably 
determine calcium homeostasis.  
 
C. Ionised Calcium 
 
Free calcium has a fundamental role in calcium homeostasis in health and is the least 
affected in the presence of parathyroid abnormalities (1). For this reason, strict 
maintenance of its equilibrium is essential. In addition to the protein-bound pool 
(mainly albumin) acting as a reservoir for free calcium to maintain normal levels, 
albumin also acts as a calcium buffer. The albumin-calcium buffer is highly pH 
sensitive (2). Changes in hydrogen ion concentration alter the charge on the acidic 
amino acid residues of the albumin molecule. This affects the number of calcium ions 
that are bound, and the fraction of tCa that is free. As such, increase in pH results in 
increased protein binding resulting in a fall in iCa, whereas a decrease in pH has the 
opposite effect.  
 
The initial method developed for iCa measurement was a bioassay with limited 
application in clinical practice which required the use of frog tissue. Currently, iCa is 
measured by potentiometry with a direct ion selective electrode (ISE) (1, 2). This is 
mostly offered on smaller blood gas analysers that are readily available in most acute 
care settings. The International Federation of Clinical Chemistry and Laboratory 
Medicine (IFCC) provides recommendations on sampling, transport, storage and an 
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ISE assay procedure for determination of iCa in heparinised whole blood and plasma 
as well as serum (10). It emphasises rapid analysis of an anaerobic sample placed on 
ice to counteract various causes of pH alteration that can alter iCa concentration. 
Dilution effects from anticoagulant solutions such as heparin should also be avoided.  
Albumin binds a relatively predictable proportion of calcium at a given pH, therefore 
multiple algorithms have been developed to derive estimates of iCa (1, 2, 11). 
However, derived iCa estimates are only approximations as calcium binding is also 
affected by several other variables including albumin, globulin, bicarbonate, citrate, 
pH and phosphate. In clinical practice, formulae predicting iCa are no longer used (1, 
11). 
As the relationship between iCa and pH is well defined and predictable, iCa can be 
mathematically “corrected” to a pH of 7.40 (2). This may produce clinically 
unacceptable estimates that do not reflect iCa in relation to the actual clinical pH 
regulation. This is particularly important in scenarios where disturbances in acid-base 
regulation are likely to occur for example chronic renal failure (12). Other scenarios 
where there are variations in albumin and/or globulin levels may also affect the ability 
of pH to predict calcium binding (2, 11). Variations in posture and venous stasis with 
prolonged use of a tourniquet may result in changes in the total protein concentration 
and pH. Consequently differences in the protein-bound and free calcium fractions 
may be observed (4). It is therefore preferable to report the uncorrected iCa to reflect 
the iCa present in the body at the time of analysis.  
 
The best assessment of calcium status is by the direct measurement of iCa. 
Nonetheless, its use is limited due to technical challenges relating to equipment 
maintenance (including frequent electrode replacement), analytical performance and 
lack of measurement standardisation. Another limiting factor, particularly in the 
outpatient setting is the requirement for rapid analysis of an anaerobic sample (1, 13). 
 
Despite the challenges associated with iCa measurement, iCa remains the most 
physiologically important measure of calcium homeostasis. Its measurement should 
be used whenever possible to diagnose disorders of calcium homeostasis (2, 14). 
Preanalytical factors that may lead to alteration in pH need to be minimised. There is 
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also a need for assay standardisation and improvement in analytical performance and 
availability of this relevant measure of calcium status in the outpatient setting. 
 
D. Total Calcium 
 
The measurement of tCa is widely available and most frequently requested to assess 
blood calcium status. Several methods are used to measure tCa – spectrophotometry 
of dye-calcium complexes, ISE’s and atomic absorption spectrophotometry. The most 
routinely used methods in clinical practice are dye binding methods such as 5-nitro-5′-
methyl-(1,2-bis(o-aminophenoxy) ethan-N,N,N′,N′-tetraacetic acid (NM-BAPTA), 
cresophthalein complexone (CPC) and Arsenazo III. Measurement of tCa relies on a 
shift in the absorption of dyes upon binding to tCa (2). These methods are 
standardised and demonstrate acceptable precision and accuracy (15, 16).  
 
The tCa is highly correlated with iCa in the absence of abnormalities in serum 
proteins or blood pH. It is therefore a reasonable substitute measurement in these 
patients (2). Conversely, alteration of calcium distribution between the bound and 
unbound fractions in some patients is responsible for the poor correlation between tCa 
and iCa. Examples are changes in serum proteins, pH; presence of certain anions that 
chelate calcium (i.e. lactate, citrate); and drugs or fatty acids that bind albumin. 
Specifically, derangements in serum proteins, particularly albumin affect tCa, in the 
absence of abnormalities in iCa. Hence the implementation of formulae to “correct” 
measured tCa for the actual concentration of albumin (2, 17). However, it remains 
inadequate in a number of clinical scenarios where iCa is the preferred measurement. 
These include: critical illness, blood transfusion containing citrate; advanced chronic 
kidney disease (CKD); hyperparathyroidism; hypercalcaemia of malignancy; and all 
neonates (1, 8). 
 
Critically ill patients have associated hypoalbuminaemia in response to stress. In 
addition, altered affinity of albumin to calcium, acid-base abnormalities and acute 
elevations of free fatty acids with heparin sulphate administration, are common in this 
setting. Interestingly, Dickerson et al demonstrated that the provision of intravenous 
lipid emulsion is not associated with hypocalcaemia, and that iCa did not correlate 
with serum triglyceride concentrations (18). In light of the multiple alterations in 
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calcium homeostasis observed in critically ill patients, tCa is not suitable for 
monitoring calcium status in critically ill patients. 
 
Late stage CKD is associated with variations in pH and albumin, which may variably 
change the different calcium fractions. Despite derivation of algorithms to predict iCa 
from tCa and albumin measurements, these tend to overestimate tCa, leading to 
inappropriate use of calcium containing phosphate binders or vitamin D and its 
analogues (19). Citrate complexes free calcium thus reducing the iCa fraction whilst 
tCa remains constant. This may occur following transfusion with citrated blood (1). In 
addition, citrate is administered as an anticoagulant for continuous renal replacement 
therapy. Here iCa is also measured in post-filter blood samples, to evaluate the 
adequacy of anticoagulation and identify citrate toxicity (20). Since direct citrate 
measurement is not routinely performed, it is not possible to estimate the reduced iCa 
fraction that occurs following binding to citrate. It is therefore essential to measure 
iCa directly in both these scenarios to identify disturbances in calcium homeostasis 
(1). 
 
In primary hyperparathyroidism, hypercalcaemia of malignancy and neonatal 
hypocalcaemia, iCa has a greater diagnostic accuracy since tCa is often normal or 
only intermittently elevated. Multiple endocrine neoplasia type 1 mostly presents with 
hypercalcaemia and this is frequently used to screen asymptomatic individuals in 
affected families (1). False negative results may have clinical consequences in these 
affected individuals.  
 
In neonates and children, critical illness alters the calcium binding to albumin, and 
other proteins may play a greater role in calcium binding. In addition, measurement of 
iCa provides a more reliable estimation of calcium status especially with the sudden 
adjustments that occurs at birth. Therefore, tCa is a poor predictor of calcium status in 
sick neonates and children compared to iCa (21).  
 
The effect of posture on serum protein and tCa has been extensively studied. A 
decrease in the hydrostatic pressure of the vascular system is associated with fluid 
shifts from the ECF into the intravascular space. A change from an upright to a supine 
position is associated with a decrease in tCa greater than its biological variation (22).  
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This is related to a concomitant decline in serum proteins, particularly albumin (23). 
Prolonged venous stasis is associated with an increase in the protein bound fraction, 
causing an increase in tCa (24-26). Positioning either arm from a horizontal point to 
below the plane of the supine body also results in increased serum protein in the blood 
in that arm (23). The iCa, being diffusible, should not alter appreciably but significant 
differences have been observed with alterations in posture (22, 25). The iCa is only 
expected to change with alterations in pH which may occur after prolonged periods of 
venous status associated with forearm exercise. These manoeuvres may introduce 
variability in laboratory results that are inconsistent with clinical findings and should 
be avoided. 
Where iCa calcium measurements are not available, tCa testing allows for screening 
of patients suspected of disorders of calcium homeostasis. However, its reliability 
relies on the absence of abnormalities in serum protein or pH. Since tCa binds 
primarily to albumin, variation in serum albumin levels alters the tCa concentration. 
As a means of improving the clinical utility of tCa measurements in patients with 
alterations in albumin concentration, equations to “correct” the tCa for serum albumin 
were derived. The following section will discuss the derivation of corrected calcium 
and its limitations. 
 
E. Corrected Calcium 
 
Several factors have been described as having a possible influence on tCa in serum 
including specific gravity (SG), total protein and albumin concentration. This led to 
derivation of formulae to “correct” the measured tCa, taking into account these 
factors. Although SG varies mainly with total protein, other factors are known to 
affect it (i.e. abnormally high urea, glucose and lipid levels). Despite an assumption 
that a similar linear relationship exists between SG and tCa, the two correlate poorly. 
In addition, poor precision and lack of widespread availability of manual SG methods, 
do not advocate its use for deriving correction factors (25, 27). Total protein and 
albumin have shown significant correlations despite low correlation coefficients (25, 
28). Corrections based on the total protein concentration are inaccurate when serum 
protein distribution is abnormal, particularly in hypergammaglobulinaemia, 
commonly encountered in patients with disorders of calcium homeostasis (13, 28). 
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Since tCa binds predominantly to albumin, a factor based on albumin was suggested 
to correct the tCa. This factor is also likely to remain valid in the presence of 
pathological elevations in globulin levels (25).  
 
Various approaches have been adopted to derive algorithms or formulae to correct 
measured tCa for albumin in patients deemed free of calcium disorders. Most are 
based on linear regression of serum tCa concentration on albumin concentration using 
specific methods for tCa and albumin measurements. The most commonly cited 
formulae in the literature used to derive cCa include (11): 
 
Orrell (1971): cCa = tCa (mmol/L) + 0.0176 (34 – [albumin] (g/L))  
Payne et al (1973): cCa = tCa (mmol/L) + 0.0246 (40.4 – [albumin] (g/L))  
Berry et al (1973): cCa = tCa (mmol/L) + 0.0227 (46 – [albumin] (g/L)) 
 
After exclusion of abnormal tCa values, linear regression of tCa on albumin was 
performed and the regression coefficient calculated (28, 29). Ideally, cCa formulae 
should be derived from patients with a wide range of albumin concentrations and 
without any disturbances in calcium homeostasis. In some, the calcium values were 
corrected to the mean albumin concentration using a formula established on their 
regression. This allowed for an arbitrary reference point for albumin concentration 
with which all individual cCa values can be compared (25). When this approach is 
applied over a wide range of albumin concentrations to derive cCa, confidence limits 
of corrected values are comparable with tCa ranges. Using linear regression, the cCa 
formula is determined as; total calcium – (slope x albumin) + (mean normal total 
calcium – intercept calcium). Additionally, most formulae apply a correction of mean 
calcium values to the mean of the normal reference interval. The most widely used 
formula in clinical practice is based on the formula derived by Payne et al. While the 
original formula derived by Payne had a factor of 0.0246, the formula commonly 
implemented used a factor of 0.02 (originated from an anonymous author in 1977, 
British Medical Journal). When albumin concentrations are substantially lower than 
30 g/L, cCa values can significantly affect clinical interpretation.  
Herewith follows a description of the derivation of cCa formulae and their limitations. 
The Payne cCa formula was derived using specific calcium (CPC) and albumin 
(bromocresol green (BCG) dye binding) methods performed in a single laboratory. 
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Two hundred samples received by the laboratory for “liver function test” were used in 
this study. The distribution of their serum tCa and albumin concentrations was 1.77 to 
2.70 mmo/L (reference range: 2.25 to 2.60 mmol/L) and 20 to 48 g/L (reference 
range: 37 to 47 g/L), respectively. Although the distribution of albumin values was 
adequate particularly in the low range, 24.5% of samples were hypocalcaemic (28). 
Since these abnormal calcium values were removed prior to performing linear 
regression, this significantly reduced the sample size. In addition, the BCG albumin 
method used is known to react with alpha globulins resulting in overestimation of 
albumin levels. Hypergammaglobulinaemia is common in patients with 
hypoalbuminaemia. This may have introduced an error in the regression coefficient.  
 
In contrast, Orrell included nine hundred and fifty four specimens for the derivation of 
cCa comprising inpatients and outpatients. However, the exclusion of patients with 
disorders of calcium homeostasis was not considered when selecting patients from 
acute wards. These patients were therefore more likely to have abnormal tCa and 
albumin concentrations. The inpatients had a mean tCa and albumin concentration of 
2.31 mmol/L and 34 g/L, respectively, whereas the outpatients were 2.42 mmol/L and 
42 g/L, respectively. The mean albumin concentration was significantly different 
between the two groups. This difference may have been attributed to the postural 
differences in these patients. Using the mean of the tCa and albumin concentrations 
for all patients may have introduced an error in the relationship between tCa and 
albumin. The correlation coefficient of tCa on albumin on linear regression observed 
by Payne (0.989) et al was significantly higher than that determined by Orrell (0.707) 
despite a larger sample size (28). This was accounted for by the inclusion of patients 
with nephrotic syndrome. Evidence suggests that these patients have higher tCa for 
the degree of hypoalbuminaemia, as there may be other macromolecules that bind 
calcium more effectively than albumin. Furthermore, these patients have higher tCa 
than those with a similar degree of hypoalbuminaemia of another cause (28). Overall, 
these formulae demonstrate inadequacies during their derivation. In addition, they 
were derived in a single laboratory using specific tCa and albumin methods despite 
their widespread use in clinical laboratories (17). The use of regression coefficients 




The use of an average regression coefficient to correct tCa has been challenged 
through the application of certain techniques (i.e. alteration in posture and prolonged 
venous stasis). The resultant differences between regressions coefficients following 
these techniques have been used to suggest the unsuitability of using an average 
coefficient. However, the variable relationship between tCa and albumin is only 
observed following these techniques. Hence corrections cannot be made in their 
presence. A free flow technique should be used when obtaining blood for tCa and 
albumin measurements. Sudden changes in posture should be avoided and noted at the 
time of sample collection in case variability is introduced by these changes (23). In 
addition, the effect of venous occlusion on plasma albumin is not comparable to the 
steady and slow decline in plasma albumin due to disease (24, 26). Overall, average 
regression coefficients can be used to correct tCa in patients with hypoalbuminaemia 
with suspicion of calcium disturbance. This is provided they are derived from patients 
without disturbances in calcium metabolism (13).  
Some cCa formulae have shown poor correlation coefficients between tCa and 
albumin with limited ranges observed over the regression lines. The calcium-albumin 
binding ratio cannot be assumed to be constant, making extrapolation at low albumin 
levels problematic. There may also be increased protein binding of calcium in the 
presence of hypoalbuminaemia. Hence the application of an average correlation 
coefficient, based on a constant linear relationship, may lead to inaccurate estimation 
of tCa at abnormally low albumin levels. This may mask the presence of 
hypocalcaemia (3). Payne et al noted that the cCa equation could not be applied in 
patients with nephrotic syndrome and hypoalbuminaemia (28). However, the albumin 
level at which these effects are most likely to occur is uncertain. 
 
Whilst the majority of these cCa formulae were previously thought to have been 
derived from clinically appropriate data, none were validated using an independent 
dataset (consisting of a wide range of tCa and albumin concentrations) and failed to 
produce similar tCa estimates (30). They also assumed that the average correlation 
coefficient relating tCa to total protein or albumin was applicable across all patients 
(3). Importantly, none of the formulae were compared to iCa to assess their 
performance. In general, use of albumin-cCa tends to underestimate the incidence of 
hypocalcaemia and overestimate the incidence of hypercalcaemia compared to 
measured tCa. This is well documented in patients with renal failure (12, 31, 32). 
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Since a strong linear relationship exists between variables that affect cCa estimations, 
it is likely that correlation coefficients will falsely overestimate the degree of 
agreement between the iCa and cCa (11). Use of cCa in critically ill surgical patients 
is also associated with significant underestimation of hypocalcaemia and 
overestimation of hypercalcaemia (33, 34). In multiple trauma patients receiving 
specialized nutritional support, cCa was overestimated in patients with hypocalcaemia 
(18). 
 
The validity of corrected calcium formulae has also been evaluated in several patient 
groups including the elderly, neonates and CKD patients. Albumin-cCa in elderly 
patients suffers from underestimation of hypocalcaemia despite being less common 
than hypercalcaemia. Hypercalcaemia is attributed to the higher incidence of 
malignant disorders and disturbances in calcium homeostasis common in these 
patients. It has been suggested that cCa formulae are only valuable in excluding 
hypercalcaemia in very old, bedbound patients (35, 36). In neonates, the relationship 
between tCa and albumin is significantly different compared to adults. The effect is 
clinically significant when correcting calcium using adult-derived cCa equations. The 
varying degrees of renal dysfunction and altered binding of calcium to albumin, is 
responsible for the poor performance of cCa in sick neonates (21). In addition, the 
higher incidence of hypoalbuminaemia does not advocate correction of tCa using a 
fixed binding ratio of tCa to albumin since it increases in hypoalbuminaemia. 
Derivation of neonate-specific equations also shows poor prediction of calcium status 
compared with iCa, particularly in detecting hypocalcaemia. Despite these limitations, 
adult-derived cCa equations are suggested for use in children one year and older (21). 
Below this age, the derivation of neonate-specific equations is limited by the 
impracticality of collecting data in the specific age groups.  
 
The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-
K/DOQI) clinical guidelines of 2003 advised maintenance of normal serum tCa, to 
avoid adverse effects on bone mineralization and increased mortality (19, 37). The 
formula derived by Orrell most closely approximates cCa in stable haemodialysis 
patients and was recommended where iCa is inaccessible (11). However, cCa 
demonstrates poor diagnostic performance in correctly classifying hypocalcaemia and 
hypercalcaemia. The risk of underestimation is significantly increased by 
	 21	
hypoalbuminaemia (less than 30 g/L) and lower total carbon dioxide concentrations 
(tCO2), particularly in later stages of CKD. Hypoalbuminaemia is also a risk factor of 
overestimating calcium status (1, 19, 32). Despite the potential adverse outcomes 
associated with false negative and false positive results, lack of availability of iCa 
measurements limit its general use in these patients.  
 
Despite these concerns, these formulae are still applied widely in clinical practice to 
screen patients with disturbances in calcium homeostasis whilst acknowledging their 
limitations. Assays for the measurement of tCa and albumin are readily available on 
automated analysers, allowing for estimations of albumin-cCa where iCa is not 
readily available. The costs of providing cCa tend to be lower than those associated 
with iCa, justifying the use of cCa formulae. Despite their poor performance in 
different patient groups, improvement of cCa formulae can substantially increase their 
clinical performance (2).  
 
F. Adjusted Calcium 
 
In March 2015 the Association for Clinical Biochemistry and Laboratory Medicine 
published a position paper with the recommendation that laboratories should develop 
and use locally derived formulae specific to their calcium/albumin methods, to report 
the “adjusted calcium”. (17). The term “adjusted calcium” was recommended for use 
rather than “corrected calcium”. Note that in this literature review the term “corrected 
calcium” (cCa) has been used consistently to refer to non-method-specific formulae, 
while the term “adjusted calcium” (aCa) has been used consistently to refer to 
method-specific formulae.  
 
Similar to cCa, aCa formulae are based on the linear regression of serum tCa 
concentration on albumin concentration using specific methods for tCa and albumin 
measurements. Numerous adjusted calcium (aCa) formulae are available. Their 
validity is restricted to the specific combination of tCa and albumin methods and 
analytical platform. Therefore their application should be limited to use in laboratories 
using the same methodology and same analytic techniques as the laboratory at which 
they are derived.  
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Most laboratories measure serum or plasma albumin by automated colorimetric dye 
binding methods. These dyes, BCG and bromocresol purple (BCP) bind albumin 
resulting in a shift in the absorption spectrum. Although automated immunochemical 
methods show better performance, they are expensive and time consuming, limiting 
their use in clinical laboratories (38). BCG albumin closely correlates with albumin 
measured by specific immunological methods in the range of 5 to 48 g/L (13). 
Therefore use of any albumin method is suggested for aCa provided it is used to both 
define and make the adjustment.  
 
The impact of a change in the method used for the calcium assay on aCa levels has 
been shown to be small and not clinically significant (39). In contrast, systemic 
differences between BCG and BCP methods are recognised (30). As previously noted, 
measurement of albumin by the BCG method is flawed by the overestimation of 
albumin concentration in the presence of increased alpha globulins. Increased alpha 
globulins are usually associated with low albumin levels. Hence, the adjustment 
varies as the positive bias in albumin levels becomes higher in hypoalbuminaemia. 
This has been minimised by use of a rapid reaction technique with newer methods 
thus reducing the effect of the globulin fraction (30). The relationship between serum 
tCa and albumin levels has been shown to be linear at albumin concentration of 32 to 
50 g/L. However, this correlation deviated at albumin levels less than 32 g/L. This is 
where the globulin fraction is likely to have a greater impact when using the BCG 
albumin method (40). Although BCP methods are more specific, albumin levels are 
underestimated in patients receiving haemodialysis, particularly continuous 
ambulatory peritoneal dialysis (CAPD). This is due an endogenous non-dialyzable 
uraemic toxin, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF), that 
inhibits only BCP binding to albumin (41). In addition, the redox status of thiol 
groups attached to albumin molecules affect its reactivity with BCP (32). The effect 
of the albumin assay on aCa values has been well demonstrated in patients with CKD 
(30, 32, 38). The change between BCG and BCP albumin methods has demonstrated 
disparity in the classification of calcium status. The change in analytical platform may 
also influence the relationship between tCa and albumin. This suggests that the 
regression coefficient of tCa on albumin depends on the analytical technique used, 
irrespective of similarities in analytical principles (40, 42). The aCa is most clinically 
useful in patients with mild disturbances in calcium homeostasis (i.e. borderline 
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hypocalcaemia and hypercalcaemia). It is therefore important that a correct regression 
coefficient is applied to avoid misclassification in calcium status.  
 
Given the discrepancy in serum albumin depends on the method and analytical 
platform used, it is suggested that laboratories derive their own suitable aCa formulae 
using their own data collected over an extended period of time. This also extends to 
laboratories using other albumin-specific methods. These formulae must also be 
monitored regularly for their validity (27, 28, 40, 42). Current recommendations by 
the Association for Clinical Biochemistry and Laboratory Medicine (ACB) are that 
laboratories determine their own aCa formulae specific for their population data and 
analytical methodology for tCa and albumin and platform. Laboratories may choose 
to derive their formula from the regression of tCa on albumin using local data, or 
validate an existing published formula (17). Their validity should be reviewed 
regularly, particularly with a change in the analytical methodology or performance 
(39, 40, 42).  
 
Several studies have reported the derivation and validation of aCa formulae that are 
appropriate for the local population and analytical methodologies. Although these 
formulae demonstrated good internal validity, like the traditional cCa formula by 
Payne at al, these aCa formulae had a tendency to underestimate hypocalcaemia and 
overestimate hypercalcaemia (27, 43, 44). It is postulated that use of the mean tCa of 
the local dataset rather than harmonized reference intervals may improve 
classification of calcium status (21, 42). Also, their performance was investigated 
only against the Payne cCa formula and not against iCa as the gold standard. 
Comparison of aCa against the gold standard marker of calcium homeostasis is 
required to confirm the true validity of locally derived aCa formulae as the iCa 
concentration is the most physiologically appropriate measure of calcium 
homeostasis. The ACB recommendation therefore prompted the derivation of an aCa 
formula specific to our tCa and albumin methods and analytical platform at GSH, as 
well as validation against iCa. 
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Introduction: Most laboratories continue to adjust serum total calcium (tCa) 
concentration for serum albumin as a surrogate marker of calcium status, despite the 
availability of ionised calcium (iCa) measurement. Current recommendations by the 
Association for Clinical Biochemistry and Laboratory Medicine (ACB) advocate that 
laboratories should use formulae specific for their tCa and albumin methods and 
analytical platforms. The National Health Laboratory Service at Groote Schuur 
Hospital (GSH) undertook to investigate this recommendation. An adjusted calcium 
(aCa) formula specific for the Roche serum tCa and albumin methods was derived 
from 3131 patients. We investigated the validity and clinical utility of this locally 
derived aCa formula. 
 
Methods: The tCa, albumin and iCa were analysed in blood from 162 inpatients and 
outpatients at GSH. Corrected calcium (cCa) was calculated using the Payne cCa 
formula, and aCa was calculated with the new aCa formula. Patients were classified 
as hypo-, normo- or hypercalcaemic using iCa, tCa, cCa and aCa measurements. 
Cohen’s kappa statistic, log-linear and logistic regression models and interclass and 
concordance correlation coefficients were used to assess agreement between tCa, 
Payne cCa and aCa against iCa (gold standard). Agreement was further assessed 
according to renal status and albumin concentrations. 
  
Results: The aCa demonstrated good correlation with iCa, but its performance was 
not significantly better than tCa or Payne cCa in correctly classifying calcium status. 
Furthermore, albumin concentration was demonstrated to predict the performance of 
the calcium status classification by the aCa and cCa formulae, irrespective of renal 
status.  
 
Conclusion: The laboratory-specific aCa formula did not perform significantly better 
than tCa and the Payne cCa formula. This implies that aCa does not add value over 
tCa where iCa measurements are not readily available. 
 
Word count: 278 
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2.4. LIST OF ABBREVIATIONS 
 
 
aCa, adjusted calcium; ACB, Association for Clinical Biochemistry and Laboratory 
Medicine; BCG, bromocresol green; BCP, bromocresol purple; cCa, corrected 
calcium; CCC, concordance correlation coefficient; CPC, O-cresophthalein 
complexone; CKD, chronic kidney disease; GSH, Groote Schuur Hospital; iCa, 
ionised calcium; ICC, interclass correlation coefficient; NHLS , National Health 
Laboratory Service; NM-BAPTA, 5-nitro-5’-methyl-1,2-bis(o-aminophenoxy)ethane-





























In clinical practice, calcium status is investigated by the direct measurement of 
ionised calcium (iCa) or its estimation from measurements of total calcium (tCa). 
Despite being the most accurate measure of calcium status, iCa measurement is not 
universally utilised due to the technical challenges associated with equipment 
maintenance, analytical performance and lack of measurement standardisation. In 
addition, the requirement for rapid analysis of an anaerobic sample to avoid 
alterations in pH, particularly limits its application in the outpatient setting (1, 2). 
Measurement of tCa remains a suitable alternative in patients without abnormalities in 
serum proteins and pH (3). Since tCa binds predominantly to albumin, formulae were 
developed to correct or adjust tCa for serum albumin (4). Consequently, most 
laboratories continue to use albumin-corrected tCa as a surrogate marker of calcium 
status (5).  
 
The validity and usefulness of adjusted or corrected calcium (cCa) formulae have 
been questioned in recent years due to wide inter-laboratory differences in cCa values 
obtained by different analytical methods and platforms used to measure serum tCa 
and albumin (4, 6). In addition, none of these formulae were validated on an 
independent dataset to assess their performance, thus indicating insufficient evidence 
for their application in clinical practice (7). The cCa formulae are mostly based on the 
linear regression of tCa on albumin using specific methods for the measurement of 
tCa and albumin (8). Payne et al described the most frequently used formula to correct 
for tCa in 1973. This formula was derived from the analysis of the linear regression 
relationship between tCa and albumin, measured using O-cresophthalein complexone 
(CPC) and bromocresol green (BCG) dye binding methods, respectively. Two 
hundred samples received by the laboratory for “liver function test” were used in this 
study. The distribution of the serum tCa and albumin concentrations was 1.77 to 2.70 
mmol/L (reference interval: 2.25 to 2.60 mmol/L) and 20 to 48 g/L (reference 
interval: 37 to 47 g/L), respectively. Although the distribution of albumin values was 
adequate particularly in the low range, 24.5% of the samples were hypocalcaemic. An 
additional correction of mean calcium values to the mean of the normal reference 
range was also applied. The cCa formula was determined as cCa = tCa (mmol/L) + 
0.0246 (40.4 – albumin (g/L)). Ideally, a cCa formula should be derived from patients 
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with a wide range of albumin concentrations and without any disturbances in calcium 
homeostasis. The exclusion of abnormal calcium values prior to performing linear 
regression analysis significantly reduced the sample size. In addition, the BCG 
albumin method used is known to react with alpha globulins resulting in the 
overestimation of albumin levels. Hypergammaglobulinaemia is common in patients 
with hypoalbuminaemia. This may have introduced an error in the linear regression 
analysis. An important limitation in this study is that the performance of this cCa 
formula was not tested against iCa to confirm its validity.  
 
This formula has been used extensively in clinical practice, but was later shown to 
perform poorly in the following clinical scenarios: critical illness, nephrotic syndrome 
and hypoalbuminaemia; blood transfusions containing citrate; advanced chronic 
kidney disease (CKD); hyperparathyroidism; hypercalcaemia of malignancy; as well 
as all neonates (1, 9-13).  The effect of hypoalbuminaemia on the performance of cCa 
formulae has been particularly well demonstrated in patients with chronic kidney 
disease. Use of cCa in this group tends to underestimate the incidence of 
hypocalcaemia and overestimate the incidence of hypercalcaemia (13-16).  
 
In recent years, with the development of newer methodologies for albumin 
measurement and the shift from BCG to bromocresol purple (BCP) albumin methods, 
the performance of this formula has fallen into further question (6, 12). As these 
methods measure albumin variably, the relationship between tCa and albumin also 
varies depending on the method used (6, 15). Several studies have demonstrated 
misclassification of calcium status, particularly in hypoalbuminaemic patients with 
use of these adjustment equations (8, 17). This implies that a single cCa formula 
cannot be used across analytical methods or platforms (12). The Association for 
Clinical Biochemistry and Laboratory Medicine (ACB) therefore recommends that 
laboratories determine their own adjusted calcium (aCa) formula specific for their 
analytical methodology and platform for tCa and albumin (8). Laboratories may 
choose to derive their formula from the regression of tCa on albumin using local 
population data, or validate an existing published formula (8). Ideally its validity 
should be reviewed regularly, particularly with a change in the analytical 
methodology or performance (6, 12, 18).  
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The National Health Laboratory Service (NHLS) at Groote Schuur Hospital (GSH) 
undertook this recommendation to derive an aCa formula specific to their tCa and 
albumin methods. The following aCa formula was derived according to guidelines 
described by the ACB (8): aCa (mmol/L) = tCa (mmol/L) – (0.0149 x [albumin] 
(g/L)) + 0.6216 (unpublished data). This aCa formula was derived using 
simultaneously run albumin and tCa data from 3131 GSH patients, with the following 
exclusion criteria: patients with renal impairment (creatinine >200 µmol/L or urea 
>15 mmol/L); hypomagnesaemia (using hypokalaemia as a surrogate marker); liver 
disease (using alanine transaminase and alkaline phosphatase >upper reference limit); 
tCa concentration <2.0 and >2.7 mmol/L; hypo/hyperparathyroidism; vitamin D 
deficiency or toxicity (excluded if vitamin D was requested); hypoadrenalism 
(excluded if cortisol was requested); patients on parenteral nutrition and patients with 
malignancy (excluded if tumour markers were requested).  
 
The aim of this study is therefore to validate the performance of this newly derived 
aCa formula against iCa, as the gold standard, in correctly categorising calcium status 
and to compare its performance to that of tCa and cCa, respectively.   
 
2.6. MATERIALS AND METHODS 
 
I. SUBJECT SELECTION  
 
A total of 162 patients (medical and surgical) were recruited from inpatient (n=10) 
and outpatient (n=152) departments at GSH over a one-year period (June 2015 to July 
2016). Exclusion criteria included: younger than 18 years of age, critically ill patients 
and patients who could not provide written informed consent. The inclusion criteria 
included patients older than 18 years of age, outpatients from medical (endocrine, 
cardiac, renal, liver and diabetic) and surgical clinics as well as healthy controls. 
Written informed consent was obtained prior to blood collection. The aim was to 
obtain a wide range of tCa and albumin concentrations. The outpatients were recruited 
on routine follow-up appointments.  
 
Venous blood was collected without (or minimal) venous stasis into calcium-balanced 
heparinised syringes (BD “calcium balanced”), transported on ice and analysed within 
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15 minutes, for iCa. In addition, blood was collected into serum separator tubes and 
allowed to clot at room temperature, after which they were centrifuged. These were 
processed for serum tCa and albumin. Prior to commencement of the study, 
institutional and research ethics approval was obtained for this study (HREC REF: 
724/2015).  
 
II. MEASUREMENT  
 
The concentration of serum tCa and albumin were measured on the Roche Cobas 
6000 using the 5-nitro-5’-methyl-1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-
tetraacetic acid (NM-BAPTA) and BCG albumin dye binding methods, respectively. 
The analytical precision for tCa was 1.47 and 1.66% at 2.22 and 3.38 mmol/L, 
respectively. The analytical precision for albumin was 1.75 and 1.83% at 33 and 49 
g/L, respectively. The iCa was measured on the Roche Cobas b123 point of care 
system, by ion selective electrode. The analytical precision for iCa was 2.99, 1.51 and 
1.34% at 0.70, 1.27 and 1.75 mmol/L, respectively.  
 
III. STATISTICAL ANALYSIS  
 
Descriptive and comparative analyses were performed using STATA Release 14 
(StataCorp 2015, College Station, TX: StataCorp LP) to assess the agreement between 
tCa, cCa and aCa against iCa. Agreement was further assessed according to renal 
status and albumin concentrations (with albumin lower than 35 g/L considered 
hypoalbuminaemic) (19). The categorisation of calcium status as hypo-, normo- or 
hypercalcaemic was based on a published reference interval for tCa (2.15-2.50 
mmol/L) (the same reference interval was used for cCa and aCa).  (19) The reference 
interval for iCa was provided by the manufacturer (1.12-1.32 mmol/L). 
 
Data was assessed using the following three methodologies: (a) Agreement between 
iCa and the three calcium measurements (tCa, cCa and aCa) in classifying patients 
according to calcium status (i.e., hypo, normo and hyper) was assessed by weighted 
Cohen kappa statistic, the log-linear model of independence as well as the quasi-
independence model. The quasi-independence model provided the best fit for our data 
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and was therefore used to further delineate findings. (b) Quantitative agreement 
between the different calcium measurements in placing patients at the same level 
relative to their respective reference intervals was assessed using interclass and 
concordance correlation coefficients. For this analysis, normalised results expressed 
as z-scores of the reference interval (calculated as [calcium – mean calcium]/standard 
deviation of 95% confidence limits) were used. (c) To assess whether albumin 
concentration and renal status influence the agreement between iCa and the different 
calcium measurements in correctly categorising calcium status, logistic regression 
modelling was used.  
Explanation of statistical tools used: 
a) Weighted Cohen kappa statistic, and log-linear models of independence and 
quasi-independence: 
These models present another way of evaluating agreement by comparing the 
observed counts to the values predicted by the log-linear models. Subsequently, they 
provide insight into the patterns of agreement and disagreement. The fit of these 
models are evaluated by the Pearson and Deviance statistics. The quasi-independence 
model includes an additional coefficient that describes agreement beyond that 
expected under independence. In addition, it calculates the odds of a calcium result 
being in agreement with the iCa.  
b) Interclass and concordance correlation coefficients: 
The interclass correlation coefficient (ICC) was used to assess the agreement of 
quantitative measurements of iCa and the three calcium measurements. The ICC has 
been demonstrated to be a more appropriate measure of agreement than linear 
regression analysis. The consistency of agreement and the absolute agreement are 
assessed in the form of a ratio of variance on a scale of 0-1, where 0 indicates 
complete disagreement and 1 complete agreement. To allow for direct comparison 
between iCa; and tCa, cCa and aCa values, calcium values were normalised to z-
scores of their respective reference intervals (the reference interval for iCa differs 
substantially from that of these other calcium measurements) (7, 20). 
The concordance correlation coefficient (CCC), rho_c was also used to assess the 
agreement between the iCa and the three calcium measurements. It is supplemented 
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by the Pearson’s coefficient (r) and bias-correcting factor (C_b), which evaluate 
precision (linear fit of the relationship) and accuracy (measures how far the best-fit 
(45-degree) line deviates from the line of identity), respectively. C_b of 1 implies no 
deviation from the 45-degree line and hence good agreement. The CCC therefore 
assesses both the correlation and agreement between iCa and the three calcium 
measurements. The CCC satisfies -1 ≤ rho_c ≤ +1, where 0 corresponds to no 
agreement and; -1 and +1 corresponds to complete negative and positive agreement, 
respectively. The CCC is complementary to the ICC in measuring agreement between 
iCa; and tCa, cCa and aCa values. Under these coefficients, agreement will be further 
assessed according to renal status and albumin concentrations.  
c) Logistic regression model: 
Using this model, we evaluated the proportion of calcium values classified correctly 
between iCa and the three calcium measurements based on renal status and albumin 
concentration. We further sought to evaluate the albumin concentration at which the 
agreement between iCa and the three calcium measurements performed poorly. This 
will assist in determining an albumin concentration cut-off whereby use of tCa or aCa 
would provide an unreliable estimation of calcium status. A p-value of <0.05 was 




I. DESCRIPTIVE ANALYSES 
 
Patients were categorised according to renal status based on a diagnosis of renal 
disease by the nephrology clinic. Patients with renal disease are referred to as the 
renal patients and patients without confirmed renal disease are referred to as non-renal 
patients. The renal group comprised of 24 patients with the remaining classified as 
non-renal (n=138). The diagnoses of the renal group included lupus nephritis, post-
renal transplant, and polycystic kidney disease. None of the patients were receiving 
renal dialysis. Their median (interquartile range) serum creatinine concentration was 
113 µmol/L (77 to 205 µmol/L). The patient characteristics of the renal and no-renal 
groups are presented in Table 1. A serum albumin concentration of 35 g/L was used to 
stratify patients as normoalbuminaemic (n=148) and hypoalbuminaemic (n=14). The 
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median (interquartile range) for serum albumin was 43 g/L (40 to 45 g/L). The range, 
median and interquartile ranges of the calcium values are presented in Table 2. 
 
 
II. COMPARATIVE ANALYSES 
 
The comparison of classification of calcium status between iCa and; tCa, cCa and 
aCa, respectively, are presented in Table 3. The percentage agreement between iCa; 
and tCa, cCa and aCa was 56%, 58% and 57%, respectively. The percentage 
agreement between iCa and the three calcium measurements did not differ 
significantly between non-renal and renal patients (Table 4). The percentage 
agreement between iCa and tCa was higher in hypoalbuminaemia (71%) than in 
normoalbuminaemia (55%). In contrast, percentage agreement between iCa; and cCa 
and aCa were higher in normoalbuminaemia than in hypoalbuminaemia (Table 4). 
The most disagreement in calcium classification was demonstrated when iCa was 
hypocalcaemic (the corresponding tCa, cCa and aCa classified these patients as 
normocalcaemic in a large number of cases); or normocalcaemic (where tCa, cCa and 
aCa classified a fair number of these as hypercalcaemic). This pattern of disagreement 
in iCa-classified hypocalcaemia was apparent irrespective of renal status or albumin 
concentration. However, disagreement when iCa-classified normocalcaemia occurred 
more frequently in non-renal and normoalbuminaemic cases.  
 
a) Agreement assessment using weighted Cohen kappa statistic, log-linear model 
of independence and quasi-independence model:  
 
The weighted Cohen’s kappa statistic demonstrated poor agreement between iCa and 
the three calcium measurements (Table 5). The log-linear independence model 
demonstrated a poor fit for our data and the quasi-independence model was therefore 
used. The coefficients and odds ratio using the quasi-independence model for 
comparison between iCa; and tCa, cCa and aCa categories are presented in Table 5. 
This model demonstrates strong agreement between iCa and tCa in hypocalcaemia 
and hypercalcaemia with positive coefficients, while the normocalcaemic group 
demonstrated less agreement. A similar pattern of agreement was demonstrated for 
cCa and aCa when compared with iCa. Furthermore, aCa was more likely to correctly 
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identify hypocalcaemic cases in true hypocalcaemia (estimated odds 2.84 x 107) than 
not.  For tCa and cCa, the estimated likelihood odds of correctly classifying true 
hypocalcaemia were 18.34 and 3.21, respectively. A similar pattern was observed 
when identifying normocalcaemic cases in true normocalcaemia (see estimated odds 
in Table 5). There were insufficient patients in the hypercalcaemia category to assess 
performance in that category. 
 
b) Quantitative agreement using interclass and concordance correlation 
coefficients:   
 
The data associated with the different calcium measurements (iCa, tCa, cCa and aCa) 
followed normal distributions. The consistency of agreement and absolute agreement 
between iCa and the three calcium measurements are described in Table 5. 
Consistency of agreement between iCa; and tCa and aCa, were demonstrated to be 
better than that between iCa and cCa. Renal patients demonstrated the best 
consistency of agreement, with better ICC for all calcium measurements. 
Furthermore, the consistency of agreement between iCa and tCa, cCa and aCa, 
respectively, was better in patients with normoalbuminaemia. While 
hypoalbuminaemic patients had better ICC’s between iCa; and cCa and aCa, their 
confidence intervals were wide.   
 
The relationship between iCa and the three calcium measurements by CCC is 
described in Table 5. Evaluation of the agreement by CCC demonstrated similar 
findings to the ICC. The Pearson’s coefficient demonstrated reasonable correlations 
between iCa and the various calcium measurements, with the best correlation 
observed between iCa and aCa. However, there was marked deviation from the line of 
identify and therefore poor agreement (see rho_c in Table 5) for all calcium 
measurements. The correlation and bias between iCa and tCa, cCa and aCa are shown 
in Figures 1 (a), (b) and (c), respectively. There is a tendency to overestimate at low 
serum calcium and underestimate at high calcium concentrations. The best agreement 
was demonstrated in the renal group, with fairly good correlation (demonstrated by 
the Pearson’s coefficients) and less deviation from the line of identity across all 
measurements (see rho_c in Table 5).  
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The agreement between iCa and tCa did not differ significantly between 
normoalbuminaemic and hypoalbuminaemic groups. However, less deviation from 
the line of identity (C_b of 0.887) was seen in the hypoalbuminaemic group. In 
contrast, cCa and aCa demonstrated better agreement and less deviation from the line 
of identity in the normoalbuminaemic group, but better correlation in the 
hypoalbuminaemic group (demonstrated by the Pearson’s coefficients).  
 
 
c) Logistic regression model to assess agreement of calcium classification with 
respect to albumin concentration or renal status: 
This model included albumin concentration and renal status as predictors of consistent 
calcium classification. Overall, albumin concentration and renal status were 
statistically significant predictors of agreement between iCa and aCa classification 
(LR χ2= 6.10, p=0.047). The same was true for cCa (LR χ2 = 6.10, p=0.047). 
Agreement between the iCa and tCa classification was related to albumin 
concentration and renal status (LR χ2 = 3,61, p=0.164) but not statistically significant. 
Therefore, further evaluation of albumin concentration and renal status as predictors 
of agreement between iCa and tCa classification was not performed. 
The coefficient for albumin concentration when holding renal status constant was 
statistically significant (p=0.018), with a one-unit increase of albumin being 
associated with increased log odds of 1.073 that the classification of calcium status 
between iCa and aCa would be the same. The presence of renal disease was 
associated with increased log odds (0.348) that classification of calcium status 
between iCa and aCa would be the same, but was not statistically significant 
(p=0.462). This implies that renal status does not significantly influence the 
performance of this calcium measurement in correctly classifying calcium status. This 
model demonstrated better agreement in the calcium classifications for cCa and aCa at 
higher albumin concentrations. However we could not demonstrate the serum albumin 





I. DISCUSSION  
 
 
The traditional marker of calcium status remains the corrected or adjusted tCa 
concentration, despite the availability of an alternative method of measurement, iCa. 
The NHLS laboratory at GSH undertook to develop and validate an albumin-aCa 
formula derived from local laboratory data. This was based on the recommendations 
by the ACB. Its performance was investigated against iCa (gold standard). 
Comparison of aCa against the gold standard marker of calcium homeostasis is 
required to confirm the true validity of a locally derived aCa formula. The pH-
uncorrected iCa, reflecting the iCa relative to the actual clinical pH, was used to 
prevent the underestimation of the true iCa concentration.  
  
The overall pattern of disagreement demonstrated in our data is consistent with 
previous studies (7, 15). There is generally poor agreement between iCa and the 
different calcium measurements. The cCa or aCa tend to underestimate the incidence 
of hypocalcaemia and overestimate the incidence of hypercalcaemia compared to the 
measured iCa. This is well demonstrated in stable CKD patients receiving 
haemodialysis with hypoalbuminaemia (13-15). Hypoalbuminaemia is an additional 
risk factor of overestimating calcium status (1, 15, 16). However, we were unable to 
demonstrate a greater incidence of misclassification specifically in renal patients. In 
fact, the pattern of disagreement when iCa was hypocalcaemic occurred irrespective 
of renal status. This difference may have been accounted for by the difference in the 
renal group in our study to that previously investigated. Only four patients in the renal 
group were hypoalbuminaemic, compared to those that were normoalbuminaemic 
(n=20). In addition, none of our renal patients were undergoing renal dialysis. The 
small number of hypoalbuminaemic and renal patients may have been insufficient in 
demonstrating the previously noted findings (7, 15).  
The best consistency of agreement and correlation with iCa was shown with aCa. The 
aCa also demonstrated the best agreement in the presence of renal disease. In contrast, 
several studies have showed unsatisfactory performance of the Payne formula and 
other correction formulae when compared to iCa in stable CKD patients on 
haemodialysis (7, 13, 14). Our renal group consisted of only 24 patients with a fairly 
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narrow range of serum creatinine concentrations. The renal group may have been 
more homogenous and thus shown better agreement compared to the non-renal group. 
The non-renal group varied widely from healthy controls to diabetic, endocrine, liver, 
cardiac and surgical patients. The heterogeneity of this patient group may have 
influenced the performance of the aCa formula. Nephropathy is a common 
complication in diabetic patients. The presence of renal damage was not assessed in 
these patients. Therefore we are uncertain whether this was a confounding factor to 
our results. Additionally, the performance of aCa formulae has not been previously 
investigated in renal patients not undergoing renal dialysis as in our study group. 
Hence the ability of these adjustment equations in correctly classifying calcium status 
specifically in this group of renal patients has not been reported. Clearly defined 
parameters for renal disease in a larger patient group would convincingly distinguish 
renal and non-renal patients and aid in delineating these findings. As these findings 
are conflicting to those previously reported in renal patients, our study does not permit 
for a more cohesive interpretation of these results. 
 
The correlation between iCa and tCa in the hypoalbuminaemia and 
normoalbuminaemia was not significantly different. This was an unexpected finding 
since tCa correlates with iCa in patients with normal serum proteins (2, 3). Overall, 
normoalbuminaemia showed better performance between iCa and the three calcium 
measurements. The aCa demonstrated the best correlation with iCa in 
normoalbuminaemic patients. However, this was not significantly different from the 
tCa and cCa measurements. The inconsistencies in the agreement and correlation 
between iCa and the three calcium measurements when stratifying by albumin 
concentration suggest that these findings are inconclusive. A larger number of 
hypoalbuminaemic patients with varying albumin concentrations is required to more 
adequately describe the agreement of tCa and aCa with iCa measurements in our 
population.  
 
Normally, serum albumin concentrations have a limited range in the non-critically ill, 
making it difficult to assess the linear relationship between tCa and albumin at these 
levels. However, Ashby et al demonstrated a deviation in the correlation at albumin 
concentrations less than 32 g/L. This is where the globulin fraction is likely to have a 
greater impact on the albumin concentration when using the BCG albumin method 
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(6). Abnormally low albumin concentrations may therefore result in clinically 
significant changes in calcium status classification (9). We were able to demonstrate 
improved agreement between iCa; and cCa and aCa classifications with higher 
albumin concentrations. Nonetheless, we were unable to demonstrate the albumin 
level at which the correlation between tCa or aCa, and albumin will deviate. Hence 
we could not establish the serum albumin concentration at which tCa or aCa are 
unreliable indicators of calcium status. However, the above findings suggest that the 
use of this aCa formula in patients with abnormally low albumin concentration may 
lead to discordant classification between iCa and aCa. This may lead to clinically 
inappropriate estimates of calcium status.  
 
Differences between the BCG and BCP albumin methods are well recognised, 
particularly in patients with CKD (15, 21, 22). Since both formulae were derived from 
serum albumin measured by the BCG method, marked differences in their 
performance were not observed.  
Overall, aCa demonstrated the best consistency of agreement and correlation with 
iCa. However, these findings were not significantly different from those shown by tCa 
and cCa. Although the quasi independence model demonstrated increased odds of aCa 
of identifying true hypocalcaemia and normocalcaemia than tCa and cCa, our other 
findings did not show better performance. The large estimated likelihood odds of aCa 
classifying true hypocalcaemia do suggest that there is a strong outcome. However, 
due to the large values in the hypocalcaemia category (aCa) relative to other values, 
the odds obtained cannot be sensibly interpreted.  
 
Previous studies have demonstrated good agreement of tCa with iCa to an extent that 
is similar to various cCa formulae (7, 23, 24). This has brought into dispute the value 
of correction or adjustment formulae. Jain et al demonstrated similar performance of a 
new cCa formula and tCa in stable haemodialysis patients using the ICC to compare 
its agreement with iCa (14). Despite demonstrating similar performance of their new 
cCa formula to our aCa formula, they recommended their formula for use in stable 
haemodialysis patients. Furthermore, agreement improved when an alternative 
reference interval was applied to iCa values. The clinical impact of using a 
harmonised reference interval for aCa when validating a local aCa formula has been 
previously investigated Davies et al. They showed that the use of a harmonised tCa 
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reference interval would have resulted in misclassification of calcium status in 
hypocalcaemia and normocalcaemia, compared to a locally derived tCa reference 
interval (18). We therefore postulate that use of a reference interval derived from our 
population data may have improved the agreement between iCa; and tCa, cCa and 
aCa. Further investigation of the agreement between iCa and aCa with the use of a 
locally derived reference interval is warranted. 
 
II. LIMITATIONS  
 
Serum creatinine levels for non-renal patients were not available and therefore 
presence of underlying renal disease could not be evaluated. This was particularly 
important since this group had a higher median for age than the renal group. The 
relatively small sample size (n=162) with a limited spread of calcium and serum 
albumin concentrations, particularly the hypercalcaemic and hypoalbuminaemic 
patients was a further limitation in our study. A larger sample size is required to 
confirm the findings in the renal and hypoalbuminaemic patients. A free flow 
technique should be used when obtaining blood for tCa and albumin measurements. 
Some patients necessitated the use of a tourniquet but we avoided prolonged venous 




This study demonstrates that the laboratory-specific aCa formula does not perform 
significantly better than tCa and the Payne cCa formula. We demonstrated that 
albumin concentration is a predictor of correct calcium classification when correction 
or adjustments are made. These results imply that adjusted calcium does not add value 
over tCa, where iCa measurements are not readily available. Further investigation into 
the agreement of iCa and aCa is warranted following the application of population 
specific tCa reference intervals.  
  









































































































2.11. TABLES  
	
	
Renal Patients  
Serum creatinine (µmol/L) 
Median 
Range 
[Interquartile range]  
 
113 
46 – 1173 







21 – 75 














18 – 81  
























































0.64 – 1.51 
 [1.10 – 1.18] 
 
2.39 
1.45 – 2.83 
 [2.30 – 2.44] 
 
2.31 
1.45 – 2.81 
 [2.25 – 2.37] 
 
2.36 
1.48 – 2.84 







0.95 – 1.35 
 [1.10 – 1.17] 
 
2.39 
1.89 – 2.81 
 [2.31 – 2.45] 
 
2.31 
2.12 – 2.59 
 [2.25 – 2.37] 
 
2.36 
2.14 – 2.66 







0.64 – 1.51 
 [1.10 – 1.19] 
 
2.33 
1.45 – 2.83 
 [2.26 – 2.43] 
 
2.32 
1.45 – 2.81 
 [2.25 – 2.43] 
 
2.36 
1.48 – 2.84 







0.64 – 1.51  
 [1.11 – 1.18] 
 
2.39 
1.45 – 2.83 
 [2.31 – 2.45] 
 
2.30 
1.45 – 2.81 
 [2.24 – 2.37] 
 
2.36 
1.48 – 2.84 







0.95 – 1.20 
 [1.00 – 1.16] 
 
2.12 
1.89 – 2.81 
 [1.98 – 2.22] 
 
2.44 
2.27 – 2.66 
 [2.35 – 2.51] 
 
2.31 
2.14 – 2.66 
 [2.26 – 2.45] 
	































   
 TOTAL CALCIUM   
CORRECTED 
CALCIUM   
ADJUSTED 
CALCIUM  















































162 12 126 24 6 147 9 3 145 14 
 
Table 3: 3 x 3 tables comparing the classification of calcium status by (a) total, (b) corrected and 














































All patients 56% 58% 57% 
Non-renal patients 55% 58% 57% 
Renal patients 62% 58% 58% 
Normoalbuminaemia  55% 63% 59% 
Hypoalbuminaemia 71% 7% 29% 
 











































 Total Calcium Corrected calcium Adjusted calcium 
Cohen kappa statistic 
(weighted) 
   
 0.244 0.100 0.156 
Quasi-independence 
model 
   
Coefficient – hypo 
Coefficient – normal 
Coefficient – hyper 
 


























ICC [95% CI] ICC [95% CI] ICC [95% CI] 
Consistency of agreement 0.672 [0.578 – 0.748] 0.550 [0.433 – 0.649] 0.682 [0.590 – 0.756] 
Renal  0.887 [0.757 – 0.949] 0.870 [0.723 – 0.942] 0.918 [0.820 – 0.964] 
Non-renal 0.506 [0.370 – 0.620] 0.193 [0.028 – 0.349] 0.414 [0.265 – 0.543] 
Normoalbuminaemia 0.665 [0.565 – 0.746] 0.612 [0.585 – 0.759] 0.643 [0.537 – 0.728] 
Hypoalbuminaemia 0.616 [0.149 – 0.858] 0.811 [0.509 – 0.935] 0.744 [0.372 – 0.910] 
Absolute agreement 0.411[-0.0935 – 
0.709] 
0.384 [-0.020 – 
0.635] 
0.382 [-0.099 – 
0.697] 
Renal 0.835 [0.460 – 0.939] 0.776 [0.183 – 0.924] 0.799 [0.013 – 0.943] 
Non-renal 0.231 [-0.093 – 
0.524] 
0.109 [-0.049 – 
0.269] 




Rho_c [95% CI] 
Pearson’s r 
C_b 
Rho_c [95% CI] 
Pearson’s r 
C_b 
Rho_c [95% CI] 
Pearson’s r 
C_b 
Overall 0.410 [0.330 – 0.490] 
0.679 
0.604 
0.383 [0.288 – 0.476] 
0.551 
0.693 





0.829 [0.709 – 0.948] 
0.890 
0.931 
0.768 [0.621 – 0.916] 
0.871 
0.882 





0.230 [0.155 – 0.303] 
0.511 
0.449 
0.109 [0.016 – 0.201] 
0.196 
0.553 





0.359 [0.280 – 0.439] 
0.666 
0.540 
0.485 [0.390 – 0.580] 
0.644 
0.753 





0.581 [0.256 – 0.905] 
0.654 
0.887 
0.156 [0.030 – 0.281] 
0.783 
0.199 




Table 5: Weighted Cohen kappa statistic and quasi-independence model data. The Interclass 
correlation coeffienct (ICC) and concordance correlation coefficient (rho_c) are represented with 
their 95% confidence intervals (95% CI). The consistency of agreement and absolute agreement 
are represented for normalized data (zCa). The concordance correlation coefficient includes the 

















Figure 1: Concordance plots demonstrating the correlation and agreement between normalised 
(a) iCa and tCa, (b) iCa and cCa, and, (c) iCa and aCa values expressed as z scores. The dashed 
line represents the line of perfect concordance (line of identity). The solid line represents the line 
of best fit. The dashed grey lines represent ±2 standard deviations of the 95% confidence 
interval. 
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CHAPTER 3: SUPPORTING DOCUMENTS 
	




















GROOTE SCHUUR HOSPITAL 
Enquiries: Dr Bernadette Eick 
E-mail : Bernadette.Eick@westerncape.gov.za 
 
 
 G46 Management Suite, Old Main Building, Private Bag X,  
  Observatory 7925       Observatory, 7935 
  
 Tel: +27 21 404 6288    fax: +27 21 404 6125   www.capegateway.go.v.za 
 
Dr F. Omar 
Division of Chemical Pathology 
NHLS – C-Floor 
NEW MAIN BUILDING 
 
E-mail:  Fierdoz.omar@nhls.ac.za / Mbali.Ndlovu@nhls.ac.za  
 
 
Dear Dr Omar 
RESEARCH PROJECT: Validation Of An Adjusted Calcium Formula Using The Roche Calcium (NM-
BAPTA) And Albumin (BCP) Methods At Groote Schuur Hospital (Mmed Dr M. Ndlovu) – Sub Study 
Linked To 288/2015 
 
Your recent letter to the hospital refers. 
You are hereby granted permission to proceed with your research and is valid until 30 October 
2016. 
Please note the following: 
a) Your research may not interfere with normal patient care. 
b) Hospital staff may not be asked to assist with the research. 
c) No additional costs to the hospital should be incurred i.e. Lab, consumables or stationary 
may be used. 
d) No patient folders may be removed from the premises or be inaccessible.  
e) Please introduce yourself to the person in charge of an area before commencing. 
f) Please discuss the study with the HOD before commencing. 
g) Please provide the research assistant/field worker with a copy of this letter as verification of 
approval. 
h) Confidentiality must be maintained at all times. 
i) Should you require additional research time beyond the stipulated expiry date, please 
apply for an extension. 
j) Once research is complete, please submit a copy of the publication or report. 
 
I would like to wish you every success with the project. 
Yours sincerely 
 
DR BERNADETTE EICK 
CHIEF OPERATIONAL OFFICER 




C.C. Mr. L. Naidoo, Dr B. Jacobs, Dr H. Vreede 
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3.3. DEPARTMENTAL APPROVAL (MEDICINE) 
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From: Mbali Ndlovu Mbali.Ndlovu@nhls.ac.za
Subject: FW: MMed Project: Dr M Ndlovu




From: Mbali Ndlovu 
Sent: 11 February 2016 10:04 AM
To: 'GSHResearch.Request@westerncape.gov.za'








From: Michelle Ahsing [mailto:michelle.ahsing@uct.ac.za] 
Sent: 11 February 2016 07:54 AM
To: Mbali Ndlovu
Cc: Eduard Jonas; Eugenio Panieri; Sean Burmeister; Marc Bernon; Paul Goldberg; Adam Boutall
(boutall@icloud.com); Claire Warden; 'Lydia Cairncross' (lydiacairn@gmail.com); Francois
Malherbe; Nadraj Naidoo; galyachinnery@gmail.com; Andrew Nicol; Pradeep Navsaria; Sorin Edu
(sorinedu@yahoo.com); Elmi Muller; David Thomson; Juan Klopper; Christos Kloppers
(jckloppers@gmail.com); Shreya Rayamajhi; Tinus du Toit; jj.venter50@gmail.com; 'Heather




























PA to Professor D Kahn
Room J45.23 | J Floor | Old Main Building 
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Most laboratories estimate total serum calcium concentration to assess calcium status. 
Calcium is a divalent cation with multiple roles, i.e. structural role in the skeleton. It 
also has numerous metabolic roles in muscle contraction, signalling, hormone 
secretion and action, coagulation, cell membrane potential and cell permeability (1). 
The majority of total body calcium (99%) is contained in the skeleton, contributing to 
the mechanical properties of the skeleton as well as providing a reservoir for calcium 
in the extracellular fluid (ECF). Extracellular calcium, including intracellular calcium 
constitutes approximately 1% to the total body calcium content (2). Calcium is 
present in serum in 3 physiological states namely, 
 
• Protein bound calcium – 30-55% (mostly bound to albumin with the 
remainder binging to globulins) 
• Calcium complexed with small anions (i.e. bicarbonate, citrate, sulfate, 
phosphate, lactate) - 5-15% 
• Free ionised calcium – 50%  
 
The free ionised calcium accounts for the biologically active form and plays a crucial 
role in calcium homeostasis in health individuals and patients with parathyroid 
abnormalities (2). In clinical practise, calcium status is investigated by the direct 
measurement of ionised calcium or its estimation from measurements of total calcium. 
Unfortunately, its direct measurement is not universally available and requires the 
rapid analysis of an anaerobic sample to avoid alterations in pH. This particularly 
continues to plague its application in the outpatient setting. However, there are 
specific clinical situations that warrant the direct measurement of ionised calcium.  
These include patients receiving transfusions with citrated blood, critically ill patients, 
and in patients with late stages of chronic kidney disease (CKD), hyperparathyroidism 
and hypercalcaemia of malignancy (2). 
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The concentration of total serum calcium varies with serum albumin concentrations 
while the concentration of the physiologically active ionised calcium concentration is 
tightly controlled by stringent endocrine regulation (3). Therefore, the derivation of an 
equation to adjust the measured total serum calcium concentration for the serum 
albumin concentration. The most commonly used equation in clinical practise is 
demonstrated below:  
 
Corrected [calcium] (mmol/L) = total [calcium] (mmol/L) + 0.02 (40 –[albumin] (g/L)) 
 
It is based on linear regression of serum calcium on albumin to derive the corrected 
calcium equation. It was also derived in a single laboratory using specific calcium (O-
cresophthalein complexone) and albumin (bromcresol green (BCG) binding dye 
reagent) methods, in patients deemed free of calcium disorders. The original equation 
derived by Payne et al, i.e. corrected [calcium] (mmol/L) = total [calcium] (mmol/L) 
+ 0.025 (40 –[albumin] (g/L)), was also based on the linear regression of serum 
calcium on serum albumin with an additional correction of the calcium values to the 
mean normal calcium concentration. The authors showed a good correlation between 
serum total calcium and albumin concentrations, however, noted that the adjustment 
could not be applied to calcium values on patients with nephrotic syndrome and 
hypoalbuminaemia (4). 
 
The serum total calcium to albumin relationship may be affected by changes in 
laboratory techniques, in particular, the shift from the BCG binding dye reagent to the 
bromocresol purple (BCP) binding dye reagent for serum albumin measurement. The 
different analytical platforms, on which the assays are performed, may also influence 
this relationship and impact the assessment of calcium status (1, 3-5). In addition, 
application of this equation in patients with abnormally low albumin concentrations 
may classify patients differently as hypocalcaemia, normal, and hypercalcaemia. In 
the presence of renal failure, corrected calcium tends to underestimate hypocalcaemia 
and overestimate hypercalcaemia compared with ionised calcium (3, 6). 
 
Several other equations have been described based on the linear regression of serum 
calcium on serum albumin mostly based on BCG determinations of serum albumin, a 
method with variable positive bias relative to the BCP method. Subsequently, they all 




Given the variability of adjustment equations between different calcium and albumin 
analytical methods and platforms, the Association for Clinical Biochemistry and 
Laboratory Medicine (ACB)|, recommended that laboratories should use equations 
based on the regression of calcium on albumin concentration specific for their calcium 
and albumin methods and analytical platforms. This may be performed either by 
locally deriving an equation or by validation of an existing equation (1). 
 
The National Health Laboratory Service (NHLS) at Groote Schuur Hospital (GSH) 
undertook this recommendation and derived an equation based on the guidelines from 
the ACB. The new adjusted calcium formula was derived using data from 3131 GSH 
patients, as per these recommendations and included the following exclusions (1): 
 
• Patients with renal impairment [creatinine >200 umol/L or urea >15 mmol/L] 
• Hypomagnesaemia [hypokalaemia as a surrogate marker  
• Liver disease [ALT/ALP > upper reference limit]  
• Total calcium concentration <2.0 and >2.7 mmol/L  
• Hypo/hyperparathyroidism i.e. PTH outside the healthy population reference 
range  
• Vitamin D deficiency/ toxicity (excluded if vitamin D was requested) 
• Hypoadrenalism (excluded if cortisol was requested)  
• Patients on parenteral nutrition 
• Patients with malignancy (excluded if tumour markers were requested) 
 
Analyses of serum calcium and albumin were performed using the Roche Cobas 6000 
5-nitro-5’-methyl-1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (NM-
BAPTA) calcium method and the BCG albumin dye binding method respectively. 
The newly derived adjusted calcium formula: 
Adjusted [calcium] (mmol/L)  
       = total [calcium] (mmol/L) – (0.0149 x [albumin] (g/L)) + 0.6216 
 
Hence, this study to assess the performance of the adjusted calcium formula against 
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the ionised calcium concentration, as the gold standard, in correctly categorizing 
patients as hypocalcaemic, normal and hypercalcaemic. Furthermore, a comparison 
will be made between ionised calcium; and total serum calcium Payne corrected 
calcium. This will assess the performance and relevance of the Payne corrected 
calcium formula. If the performance of the adjusted calcium formula is deemed 
adequate, it would be a feasible alternative to the current Payne corrected calcium 
formula. In addition, the NHLS undertook to develop several other formulae for the 
different combination of serum calcium and serum albumin methods in use within the 
NHLS laboratories nationally, using the same guidelines recommended by the ACB. 
The same mathematical methodology was applied to derive these formulae and in 
principle, it may be possible that validation of two formulae would be adequate in 
assessing the performance of the other formulae developed similarly. 
 
3. Aims and objectives 
 
a) Testing of the performance adjusted calcium formula for the Roche Cobas 
6000 NM-BAPTA serum calcium and BCG serum albumin methods on a 
larger sample size (n=150). 
b) Categorisation of calcium status as hypocalcaemia, normal and 
hypercalcaemia, based on the ionised calcium, total serum calcium, Payne 
corrected calcium and adjusted calcium. 
c) Comparison of the performance of the total serum calcium, corrected calcium 
(Payne) and the adjusted calcium against ionised calcium (gold standard), in 
correctly classifying calcium status. 
d) Testing the performance of the adjusted calcium formula for the Siemens 
ADVIA 1800 o-Cresolphthalein complexone (CPC) serum calcium and BCG 
serum albumin methods on the same samples by performing similar analyses 
of the total calcium, corrected calcium (Payne) and adjusted calcium against 






II. METHODS  
	
1. Study design  
 
The study is a comparative analytical study that will be an extension of a previously 
approved study by the University of Cape Town Human Research Ethics Committee 
(HREC/REF: 288/2015 - Derivation and testing of adjusted calcium formula for the 
Roche calcium (BAPTA method) and albumin methods (BCG method)). The present 
study will aim to compare the performance of the new adjusted calcium formula 
against the ionised calcium using a larger sample size. The previous study was limited 
by a smaller sample size and inability to assess performance of the new adjusted 
calcium formula in patients with low albumin concentrations. In addition to the above-
mentioned adjusted calcium formula, several other formulae were developed for the 
different combinations of serum calcium and albumin methods used within the NHLS. 
In principle, validation of another formula derived mathematically similarly to the 
GSH formula, may not necessitate validation of the other formulae. Testing of the 
adjusted calcium formula for the Siemens ADVIA 1800 calcium (CPC method) and 
albumin methods (BCG method) against the ionised calcium to assess its 
performance. 
 
2. Subject selection 
 
For the present study, we aim to investigate the performance and suitability of the 
new formula in 200 patients selected for a wide range of serum albumin and calcium 
concentrations. The following exclusion criteria will apply: 
 
• Patients < 18 years 
• Critically ill patients 
• Patients who do not provide written consent to participate in the study 
Patients will be recruited from the outpatients department (i.e. endocrine, liver, renal 






Serum samples for calcium and albumin as well as whole blood for ionised calcium 
will be obtained after informed consent. Access restricted computer records will only 
be available to staff involved in the study to ensure patient privacy and 
confidentiality. Outpatients will not be compensated and the visit, at which bloods are 
drawn, would be part of their routine follow-up appointment. The attending clinician 




Venous blood will be collected without venous stasis, into calcium-balanced 
heparinised syringes and transported on ice and analysed within 15 minutes, for 
ionised calcium determination. In addition, blood will be collected into serum 
separator tubes, centrifuged and processed for serum albumin and calcium 
determinations. A trained person using an aseptic technique will collect a total volume 
of 10 ml of blood. The concentration of serum total calcium and serum albumin will 
be measured using the NM-BAPTA calcium method and BCG albumin method 
respectively on the Roche Cobas 6000 analyser at Chemical Pathology Laboratory, 
NHLS GSH. Ionised calcium testing will be performed on the Roche Cobas b 123 
point of care (POC) system, by ion selective electrode. Furthermore, the concentration 
of serum calcium and serum albumin will also be measured using the CPC calcium 
method and the BCG albumin method respectively on the Siemens ADVIA 1800 
platform at Chemical Pathology Laboratory, NHLS Tygerberg Hospital. This will 
enable the validation of another formula derived mathematically similarly to the 
formula developed at GSH.1  
 
In addition, data will be extracted from the laboratory information system (LIS) in 
patients where serum calcium and albumin were measured, for comparative analyses 








III. DATA ANALYSIS  
 
Comparative and descriptive analyses will be performed using Microsoft Excel and 
Statistica to assess the performance of total calcium; Payne corrected calcium and 
adjusted calcium against ionised calcium.  
• Categorisation of data will be performed using ionised calcium as the gold 
standard. Published reference ranges will be used as well as the medical 
decision limits in correctly classifying patients as hypocalcaemic, normal and 
hypercalcaemic as follows: 
o Total serum calcium: 2.15-2.50 mmol/L (Adult reference range, Tietz 
Clinical Guide to Laboratory Tests, 4th Edition, page 202) 
o Ionised calcium: 1.12 – 1.32 mmol/L (Roche Cobas b 123 POC 
system) 
• The agreement will be described for the total calcium, corrected calcium and 
adjusted calcium against the ionised calcium, as well as against each other. 3 
• The corrected and adjusted calcium will be compared using ordinary linear 
regression analysis and the Wilcoxon test (p-value < 0.05 will be considered 
statistically significant).3 
• Results will be stratified according to the albumin concentration to assess at 
which albumin levels the formulae perform adequately.  
 




Prior to commencing the study, this protocol will be presented to the Department of 
Clinical Laboratory Sciences Research Committee followed by submission to the 
Health Sciences Human Research Ethics Committee (HREC) of the Faculty of Health 





The results will be used for the purpose of obtaining an MMed qualification through 
the University of Cape Town. In addition, this study will act as a pilot study for the 
application of the new adjusted calcium formula in clinical practise. Should there be 
obvious findings from this study, it will determine changes in clinical practise and 
failure to do so, may necessitate further studies to validate the adjusted calcium 
formula. This study will also be for presentation at the annual Pathology congress 







August 2015: Protocol submission for approval by the Department of Clinical 
Laboratory Sciences Research Committee followed by submission to the UCT HREC 
for approval. 
September – December 2015: Sample collection and data analysis; as well as 
preparation of an abstract for presentation at the 2016 American Association for 
Clinical Chemistry Annual Meeting & Clinical Lab Expo – pending approval by the 
HREC.  
June - August 2016: Writing up of data and preparing mini-dissertation as well as 




Expenses anticipated will be for analysis of serum total calcium and albumin as well 
as ionised calcium. These expenses will be covered by the Division of Chemical 
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3.6. INFORMED CONSENT FORM 
 
 
DEPARTMENT OF PATHOLOGY 
DIVISION OF CHEMICAL PATHOLOGY 
CONSENT FORM 
 
Investigators: Dr M Ndlovu, Dr F Omar & Dr H Vreede 
 
VALIDATION OF AN ADJUSTED CALCIUM FORMULA USING THE 
ROCHE CALCIUM (NM-BAPTA) AND ALBUMIN (BCG) METHODS AT 
GROOTE SCHUUR HOSPITAL 
 
Calcium is the most abundant mineral in the body that is an essential part of bones 
and teeth. The heart, nerves and blood clotting systems also need calcium to work. In 
the blood, calcium is present as a free form, known as the ionised calcium. This is the 
active calcium and its levels therefore reflect calcium balance in the body.  In 
addition, calcium is also bound to a protein in the blood that is made by the liver 
called albumin. 
 
Free calcium is affected by a many factors such as exposure of the blood sample to 
air, time taken for the blood to be drawn from your arm to when it is measured in the 
laboratory; and high temperatures. This means that special precautions need to be 
taken in order to ensure a correct laboratory result. As such, most laboratories offer an 
alternate method for its estimation. This involves measuring all the calcium in the 
blood (known as the total calcium) and the albumin level. Both the total calcium and 
albumin values are then applied into a formula to calculate an “adjusted” calcium 
level. This adjusted calcium is thought to provide a good indication of the free 
calcium level in the blood.  
 
This study aims to evaluate the newly developed adjusted calcium formula at Groote 
Schuur Hospital, NHLS laboratory. The adjusted calcium derived from this new 
formula will be compared to the free calcium as well as the total calcium in order to 
assess the ability of this formula to correctly reflect calcium balance in the body.  
	 65	
For this purpose we would like to obtain blood from you. A maximum of 10 ml (~2 
teaspoons) blood will be taken in order to measure the levels of total calcium, free 
calcium and albumin. Blood will be taken by inserting a needle into a vein in your 
arm. This may cause some discomfort. There is also a theoretical risk of infection but 
sterile procedures will be used to minimise this risk and only qualified persons will 
draw blood. The blood will then be taken to the laboratory for measurement of total 
calcium, free calcium and albumin.  
 
Participant: I, ………………………………(name and surname) agree to participate 
in the above study and hereby give permission that my blood may be taken and 
analysed. 
I understand that I will undergo the following: 
1. Venous blood will be taken: 
a. Blood will be drawn directly into a balanced-heparinised syringe for 
ionised calcium measurement. 
b. Blood will also be drawn into a gel separator tube (5 ml) for albumin 
and total calcium measurement.  
c. Risk of infection will be minimized by using sterile procedures, and a 
suitably qualified person will take all blood samples. 
2. I further understand that a portion of these blood samples may be stored for: 
a. Possible reanalysis. 
b. Further research studies, subject to the approval of the University of 
Cape Town Human Research Ethics Committee and that any 
information from such research will remain confidential. 
c. However, I can ask that my blood be not stored and destroyed after this 
use. 
Regarding storage of your blood, please tick the appropriate block below: 
 
• I am happy to have my blood stored:  o 
• I am NOT happy to have my blood stored: o 
 
3. I understand that any abnormal results will be provided to the clinician in 
charge of my treatment and may therefore be used in my medical 
management. 
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4. I have been informed that:   
a. No blood will be stored for DNA / genetic analysis   
b. The investigators are under the obligation to respect medical 
confidentiality and every effort will be made to protect my 
confidentiality. My name will not be used in any study report. 
I UNDERSTAND THAT I MAY WITHDRAW MY CONSENT FOR ANY 
ASPECT OF THE ABOVE STUDY AT ANY TIME WITHOUT AFFECTING MY 
FUTURE MEDICAL CARE. 
ALL OF THE ABOVE HAVE BEEN EXPLAINED TO ME IN A LANGUAGE 
THAT I UNDERSTAND AND MY QUESTIONS HAVE BEEN ADEQUATELY 
ANSWERED 
 
Contact details: For any queries related to the research study, you can call the UCT 
Faculty of Health Sciences Human Research Ethics Committee contact number: 
021 406 6492 or the investigators at the Division of Chemical Pathology: 021 404 
4135/4118/5429 
 





Informed consent obtained by: 
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OVERVIEW 
Clinical Chemistry, issued monthly, is published in print and 
electronically by the American Association for Clinical Chemistry. 
The journal welcomes contributions, either experimental or 
theoretical, in the field of laboratory medicine. It is the leading 
forum for peer-reviewed, original research on innovative practices 
in today’s clinical laboratory. In addition to being the most cited 
journal in the field, Clinical Chemistry has the highest Impact 
Factor among journals of clinical chemistry, clinical (or anatomic) 
pathology, analytical chemistry, and the subspecialties, such as 
transfusion medicine and clinical microbiology. 
Submissions of the following nature are welcomed: 
• Basic materials or principles 
• Analytical techniques 
• Molecular diagnostics 
• Test utilization or testing-related health or financial outcomes 
• Instrumentation 
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• Data processing 
• Statistical analyses of data 
• Clinical investigations in which laboratory testing has played a 
major role 
• Laboratory animal studies of chemically oriented problems of 
human disease 
Contributions should consist of subject matter that is original and 
significantly advances the state of knowledge of clinical chemistry, 
and conclusions that are justified from the design of the 
experiments and the data presented. The information must be 
sufficiently detailed to permit replication of the work by a 
competent worker in the field. Lastly, the writing must be clear, 
concise, and grammatically correct. 
 
Equal consideration is given to original manuscripts in English from 
any country, regardless of membership in the Association. It is, 
however, advised that all non-English speaking authors enlist the 
aid of a native-English speaking colleague to correct English 
language usage before submission. Submissions must adhere to 
the “Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals” (1). 
All Clinical Chemistry submissions, correspondence, and reviews 
must be in English. Manuscript content and writing responsibility 
remains with the author; however, several professional 
writing/editing services are available to assist authors. Clinical 
Chemistry does not endorse any editing service nor is Clinical 
Chemistry responsible for any services performed. These include 













Contributions may be submitted via the manuscript tracking system 
at http://submit.clinchem.org. The “Information for Authors” will 
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offer assistance with journal style and requirements. Please 
contact the Editorial Office via e-mail should you have any 
questions or need assistance: clinchemed@aacc.org. 
References: 
1 International Committee of Medical Journal Editors. Uniform 
requirements for manuscripts submitted to biomedical 
journals. Ann Intern Med 1997;126:36-47. [Full Text] 
Back to Top 
 
STANDARDS FOR REPORTING SCIENTIFIC DATA 
• Description of Analytical Methods and Results 
• Statistics 
• Studies with Human Subjects 
• Animal Studies 
• NIH Funding/Open Access Requirements 
• Checklist for the Description of Sequence Variants at the Human 
Genome Variation Society 
 
DESCRIPTION OF ANALYTICAL METHODS AND RESULTS 
Manuscripts describing the development and evaluation of the 
performance of methods and instruments should discuss linearity, 
imprecision, analytical specificity, recovery, lower limit of detection, 
comparability with other analytical methods, lower limit of 
quantification and reference interval(s). Some clinical data are 
usually needed. 
Document the analytical advantages of the new or modified 
method over existing methods. 
Analytical method validations should conform to the protocols and 
requirements in the Center for Drug Evaluation and Research 
(CDER) Guidance for Industry: Bioanalytical Method Evaluation, 
2001 (1). 
Calibration curves and linearity: Data for these studies should be 
analyzed by linear regression analysis (if a linear response is 
obtained) and should include the slope, intercept, r2, standard 
deviation of residuals, and the standard deviations of the slope and 
intercept. 
Standard deviations of repeated points may be included. 
In preparing nonlinear calibration curves, authors may use any 
objective, statistically valid method but must specify the method 
used (see, e.g., (2)). 
Imprecision: Studies must include estimates of "within-run" and 
"total" standard deviations (2). Each should be determined at low, 
	 70	
normal, and above-normal concentrations with use of specimens 
that are in an appropriate biological matrix. 
One method for estimating both within-run and total standard 
deviations is the analysis of variance experiment described in 
NCCLS EP5-T (3), which calls for two replicates per specimen per 
run and two runs per day for 20 days. This permits separate 
estimation of between-day and between-run, within-day standard 
deviations, as well as within-run and total standard deviations. 
For acceptable alternatives that include only one run per day, see 
the cited document. 
Indicators of Accuracy ("Trueness"): Accuracy (or “trueness” in the 
recent nomenclature) of a new method can be estimated by (a) 
analyses of certified Reference Materials by the new method or (b) 
comparisons of results of a new method with results of a 
Reference Method. These are the only accepted approaches to 
trueness. When neither is available, other evidence relevant to the 
ability of the method to measure the analyte (measurand) is 
needed. Recovery studies involve analyses after known amounts 
of analyte are added to the biological fluid on which the 
determination will be performed. Recovery of added analyte should 
be calculated [(final concentration – initial concentration)/added 
concentration], not the observed final concentration as a proportion 
of expected final concentration. 
Interference studies should be performed to assess the effects of 
common interferents, including lipid particles, hemoglobin, bilirubin, 
and components of uremic plasma. Exogenous materials, such as 
ingredients of blood collection containers (tubes) and commonly 
used or commonly coadministered drugs that might interfere with 
the determination, should also be tested for interferences. 
Selection of materials to test should be guided by an 
understanding of the chemistry and physics of the measuring 
system. Thus chemicals that are structurally similar to the analyte 
should be tested to assess the selectivity of the method. (The term 
“selectivity” is preferred over specificity; selectivity can be 
quantified.) In characterizing non-spectrophotometric methods, 
chemicals that may interfere in the detection system should be 
studied more intensively than chemicals that are historically 
important for interference in spectrophotometric methods. 
Comparison-of-methods studies should compare results by the 
new or proposed method with those by a reference-quality method 
or other generally accepted analytical method for which assay 
performance is documented (4, 5). 
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It is desirable to test 100 to 200 different samples from patients 
who have been selected to include a wide variety of pathologic 
conditions and to present a range of values for the analyte that 
includes those likely to be encountered in routine application. 
For a table of the required number of samples, see Linnet (6). 
If regression analysis is used for statistical evaluation of the data, 
supply slopes and intercepts (and their standard deviations) and 
standard deviations of residuals (Sy|x, often called standard errors 
of estimates). Unbiased (e.g., Deming) regression is typically 
required (7). A program to perform Deming regression is available 
online as a supplement from this journal (8). 
The correlation coefficient has limited utility. Residuals plots [e.g., 
Bland-Altman (9, 10)] are often useful. On the horizontal axis, plot 
the mean of results by the two studied methods, not the result of 
one method. 
Analytical sensitivity and detection limit: These terms are 
commonly confused. The International Union of Pure and Applied 
Chemistry defines analytical sensitivity as the ability of an 
analytical procedure to produce a change in signal for a defined 
change of the quantity. This is often visualized as the slope of the 
calibration curve. 
The limit of detection (LOD) is defined as the lowest concentration 
or amount of an analyte that can be reliably identified as being 
qualitatively present in the sample. The limit of quantification 
(LOQ) is defined as the lowest concentration or amount of analyte 
that can be reproducibly quantified in a sample. The most 
acceptable criteria for ascertaining the LOQ is the concentration of 
analyte that can be measured with an imprecision of less than 20% 
and a deviation from target of greater or less than 20% (1). The 
operational definition of the LOD and LOQ must be supplied by the 
author. Additional considerations related to this topic are presented 
by Linnet (11). 
Analytical quality: Results obtained for the performance 
characteristics should be compared objectively with well-
documented quality specifications, e.g., published data on the 
state-of-the-art performance required by regulatory bodies such as 
CLIA 88, or recommendations documented by expert professional 
groups (12). 
Reference interval (normal range): Depending on the conclusions 
of the accuracy studies, modification of an accepted reference 
interval may be indicated. Description of the reference interval 
study should include details about sampling; selection of subjects, 
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including their number, age, and sex distribution; the statistical 
method for summarizing the results (13); and other factors that 
would influence the values obtained. 
Mass spectrometric assays must be evaluated for matrix effects 
(ion suppression or enhancement) (14, 15). 
Chromatograms: Chromatograms from gas-liquid and liquid 
chromatography should usually be presented so that readers can 
see the efficiency of the separation and observe the resolution 
from interferents in the matrix. Similar images are often needed for 
electrophoretic separations. 
Enzyme activities: Enzyme activities may be expressed in 
international units (U) or katals. Temperature and other key assay 
features must be described in the text or by reference to a 
published method. 
When first mentioned in the text, enzymes (whether measured by 
activity or mass assays) must be numbered (EC no.) in 
accordance with the recommendations of the Nomenclature 
Committee of the International Union of Biochemistry and 
Molecular Biology on the Nomenclature and Classification of 
Enzymes (16). 
References: 
1 Center for Drug Evaluation and Research (CDER) Guidance for 
Industry: Bioanalytical Method Evaluation, 2001. 
2 Linnet K, Boyd JC. Selection and analytical evaluation of 
methods – with statistical techniques. In: Burtis CA, Ashwood 
ER, Bruns DE. Tietz textbook of clinical chemistry and 
molecular diagnostics. 4th ed. St. Louis: Saunders, 2006: 
353-407. 
3 NCCLS Tentative Guideline EP5-T. User evaluation of precision 
performance of clinical chemistry devices. Wayne, PA: 
National Committee for Clinical Laboratory Standards, June 
1984. 
4 Carey RN, Garber CC. Evaluation of methods. In: Kaplan LA, 
Pesce AJ, eds. Clinical chemistry. Theory, practice and 
correlation, 2nd ed. St. Louis: CV Mosby, 1989:290–310. 
5 Koch DO, Peters T Jr. Selection and evaluation of methods. In: 
Burtis CA, Ashwood ER, eds. Tietz textbook of clinical 
chemistry, 2nd ed. Philadelphia: WB Saunders, 1994:508–
25. 
6 Linnet K. Necessary sample size for method comparison studies 
based on regression analysis. Clin Chem 1999;45:882–94. 
[Abstract/Full Text] 
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7 Linnet K. Evaluation of regression procedures for methods 
comparison studies. Clin Chem 1993;39:424–32. [Full Text] 
8 Martin RF. General Deming regression for estimating systematic 
bias and its confidence interval in method-comparison 
studies. Data supplement. GDR: Executable program for 
general Deming regression calculations and graphics. 
[Abstract/Full Text/Data Supplement] 
9 Bland JM, Altman DG. Statistical methods for assessing 
agreement between two methods of clinical measurement. 
Lancet 1986;1:307–10. [Abstract] 
10 Altman DG, Bland JM. Commentary on quantifying 
agreement between two methods of measurement. Clin 
Chem 2002;48:801-2. [Extract/Full Text] 
11 Linnet K, Kondratovich M. Partly nonparametric approach for 
determining the limit of detection. Clin Chem 2004;50:732-
40. [Extract/Full Text] 
12 Fraser CG, Petersen PH. Analytical performance 
characteristics should be judged against objective quality 
specifications. Clin Chem 1999;45:321–3. [Extract/Full Text] 
13 Solberg HE. Establishment and use of reference values. In: 
Burtis CA, Ashwood ER, eds. Tietz textbook of clinical 
chemistry, 4th ed. St. Louis: Saunders, 2006:425–48. 
14 Annesley TM. Ion Suppression in Mass Spectrometry. Clin 
Chem 2003;49:1041-44. [Full Text] 
15 Matuszewski BK, Constanzer ML, Chavez-Eng CM. 
Strategies for the assessment of matrix effect in quantitative 
bioanalytical methods based on HPLC-MS.MS. Anal Chem 
2003;75:3019-30. [Abstract] 
16 International Union of Biochemistry and Molecular Biology, 
Nomenclature Committee. Enzyme nomenclature 1992. San 
Diego: Academic Press, 1992:862pp. 
 
STATISTICS 
Describe statistical methods with enough detail to enable a 
knowledgeable reader with access to the original data to verify the 
reported results. 
When possible, quantify findings and present them with 
appropriate indicators of measurement error or uncertainty. 
Avoid sole reliance on statistical hypothesis testing, such as the 
use of P values, which fails to convey important quantitative 
information. 
When appropriate, confidence intervals should be presented; see, 
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e.g., Harris (1), Henderson (2), and references therein. 
References: 
1 Harris EK. On P values and confidence intervals (why can't we P 
with more confidence?) [Editorial]. Clin Chem 1993;39:927-8. 
[Full Text] 
2 Henderson AR. Chemistry with confidence: should Clinical 
Chemistry require confidence intervals for analytical and 
other data? [Opinion]. Clin Chem 1993;39:929-35. 
[Abstract/Full Text] 
 
STUDIES WITH HUMAN SUBJECTS 
Authors are responsible for ensuring compliance of human studies 
with the Helsinki Declaration of 1975 as revised in 2008: 
http://www.wma.net/en/30publications/10policies/b3/index.html. 
Approval by the appropriate institutional committee on human 
research (Institutional Review Board) must be documented in the 
manuscript and, unless excepted by that committee, informed 
consent of all participants studied for the report must be included. 
 
ANIMAL STUDIES 
Authors are responsible for ensuring that studies of animals are in 
accordance with the Committee on Care and Use of Laboratory 
Animals. The information can be found in the Guide for the care 
and use of laboratory animals. Washington, DC: Institute of 
Laboratory Animal Resources, National Research Council, 
1985:83pp. 
 
NIH FUNDING/OPEN ACCESS REQUIREMENTS 
The National Institutes of Health (NIH) has implemented its "Policy 
on Enhancing Public Access to Archived Publications Resulting 
from NIH Funded Research." This policy requests that authors 
reporting research that is funded (in whole or part) by a current 
NIH grant submit to NIH PubMed Central (PMC) manuscripts after 
they have been peer reviewed and accepted for publication in 
scientific journals. The “accepted manuscript” is the version of the 
manuscript after the author’s final revision but before post-
acceptance editing and copyediting. The Policy is available online 
at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-05-
045.html. The policy applies to manuscripts accepted for 
publication in Clinical Chemistry on or after May 2, 2005. 
The policy requests that the release date to the public be within 12 
months after the official date of final publication. Clinical 
	 75	
Chemistry’s existing policy that has been in effect since the 
Journal first appeared online in 1998 is to make all content publicly 
available 12 months after publication date. Authors have the option 
to request that their papers be made freely available immediately 
at the time of online publication, for a fee of $3500. For more 
information or to request open access publication, contact the 
Editorial Office at clinchemed@aacc.org. 
If an author chooses to submit an accepted manuscript to PMC, he 
or she will be asked to indicate when that manuscript should be 
made available to the public. Consistent with our existing policy, 
the American Association for Clinical Chemistry (AACC) grants the 
author permission to allow public release of the accepted 
manuscript through PMC 12 months after publication in Clinical 
Chemistry. 
Accepted manuscripts and published articles in Clinical Chemistry 
are protected by AACC’s copyright at the time of publication and 
thereafter. All copyright restrictions apply. 
The author’s manuscript available on the PMC site is not the 
Clinical Chemistry article. This version of the manuscript may 
contain factual errors that were detected during the post-
acceptance editing phase. Data, text, conclusions, tables, and 
figures may all differ from the published version available at 
www.clinchem.org. The final published version is the Clinical 
Chemistry article. Clinical Chemistry assumes no responsibility for 
earlier versions. 
The AACC requires that authors add the following disclaimer to the 
manuscript before sending it to PMC: 
"This is an un-copyedited authored manuscript copyrighted by the 
American Association for Clinical Chemistry (AACC). This may not 
be duplicated or reproduced, other than for personal use or within 
the rule of 'Fair Use of Copyrighted Materials' (section 107, Title 
17, U.S. Code) without permission of the copyright owner, AACC. 
The AACC disclaims any responsibility or liability for errors or 
omissions in this version of the manuscript or in any version 
derived from it by the National Institutes of Health or other parties. 
The final publisher-authenticated version of the article will be made 
available at http://www.clinchem.org 12 months after its publication 
in Clinical Chemistry.” 
Authors may contact Clinical Chemistry via e-mail at 
clinchemed@aacc.org with any questions related to submitting 
their accepted manuscripts to PMC. More information from NIH 
can be found at http://publicaccess.nih.gov/FAQ.htm. 
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CHECKLIST FOR THE DESCRIPTION OF SEQUENCE 
VARIANTS AT THE HUMAN GENOME VARIATION SOCIETY 
Requirements for the description of sequence variants can be 
found at http://www.hgvs.org/mutnomen/checklist.html. 
Back to Top 
 
TOOLS FOR DIAGNOSTIC ACCURACY 
• Studies of Diagnostic Accuracy (STARD) 
• Outcomes Studies (CONSORT) 
• Minimum Information about a Microarray Experiment (MIAME) 
• Minimum Information about Quantitative Real-Time PCR 
Experiments (MIQE) 
 
STUDIES OF DIAGNOSTIC ACCURACY (STARD) 
STARD Checklist [PDF]  
STARD Flowchart [PDF] 
Explanatory document, with examples: 
http://www.clinchem.org/cgi/content/full/49/1/7 
STARD guidelines: http://www.clinchem.org/cgi/content/full/49/1/1 
For studies of diagnostic accuracy of tests, complete the STARD 
Checklist for Evaluations of Diagnostic Accuracy (1) electronically 
upon submission. Do not send the checklist via e-mail or upload it 
as supplemental material. 
The STARD statement (1) and explanatory document (2) provide 
guidance helping authors to modify their manuscript as needed to 
provide the requested information. Guidelines include: 
-Provide literature reference(s) describing the evaluated test(s) and 
criterion "gold standard" test(s) or include detailed descriptions of 
them. 
-Follow accepted methodologic standards including the following: 
1 Specify spectrum of evaluated patients (age and sex 
distributions, eligibility criteria, and summary of symptoms or 
disease stage). 
2 Analyze pertinent subgroups of subjects (e.g., symptomatic and 
asymptomatic patients). 
3 Avoid verification bias (usually by application of a "gold-standard" 
test to all subjects rather than to a clinically selected subset). 
4 Categorize test results and patients independently to avoid 
reviewer bias (usually by performance of tests with blinding 
to patient information and vice versa). 
5 Provide confidence intervals (or SE) for indices of diagnostic 
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accuracy such as sensitivity/specificity, likelihood ratios, and 
areas under receiver-operating characteristic (ROC) curves 
(3). 
6 Indicate the number of indeterminate test results and their use (if 
any) in further data analysis. 
7 Provide laboratory data on analytical imprecision of the test 
(usually day-to-day CV at two or more concentrations) or 
reproducibility of observer interpretation (e.g., for a visually 
read, dichotomous [positive/negative] test). 
-A flow diagram is strongly recommended (1, 2). 
-When evaluating diagnostic accuracy in clinical studies, simple 
testing of the significance of differences between mean values of 
patient groups (e.g., by Student’s t-test) provides insufficient 
information to assess diagnostic accuracy. 
-Scatter plots of data, calculations of diagnostic sensitivities and 
specificities and their confidence intervals (3), and use of 
approaches such as ROC curves (4), cumulative distribution 
analyses (5), likelihood ratios (6), and discriminant analysis (7) 
provide information that is appropriate to specific situations. 
-Confidence intervals should be provided (1). 
-Discussions of predictive values in illustrative settings may be 
useful additions to assess the potential clinical utility of tests. 
-Analysis of serial measurements requires special attention (8). 
References: 
1 STARD Group. Towards complete and accurate reporting of 
studies of diagnostic accuracy: the STARD statement. Clin 
Chem 2003;49:1-6. [Abstract/Full Text] 
2 Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, 
Irwig LM, et al. The STARD statement for reporting studies of 
diagnostic accuracy: explanation and elaboration. Clin Chem 
2003;49:7-18. [Abstract/Full Text] 
3 Harper R, Reeves B. Reporting of precision of estimates for 
diagnostic accuracy: a review. BMJ 1999;318:1322-3. [Full 
Text] 
4 Zweig MH, Campbell G. Receiver-operating characteristic (ROC) 
plots: a fundamental evaluation tool in clinical medicine 
[Review]. Note that in Figs. 4-12 in this paper, the labels for 
the x-axis at the top and bottom are reversed. The (correct) 
dual labeling of the x-axis solves the problem of whether to 
plot specificity or 1 - specificity on the x-axis. Clin Chem 
1993;39:561-77. [Abstract/Full Text] 
5 Krouwer JS. Cumulative distribution analysis graphs-an 
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alternative to ROC curves [Technical Brief]. Clin Chem 
1987;33:2305-6. 
6 Albert A. On the use and computation of likelihood ratios in 
Clinical Chemistry. Clin Chem 1982;28:1113-9. [Abstract/Full 
Text] 
7 Solberg HE. Discriminant analysis. Crit Rev Clin Lab Sci 
1978;9:209-42. 
8 Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of 
serial measurements in medical research. Br Med J 
1990;300:230-5. 
 
OUTCOMES STUDIES (CONSORT) 
Outcomes studies (CONSORT) 
CONSORT Checklist [PDF]  
CONSORT Flowchart [PDF] 
The CONSORT statement (1), although designed for randomized 
controlled trials and used for therapeutic rather than diagnostic 
interventions, is recommended as an often-useful guide. 
For questions, contact Clinical Chemistry via e-mail at 
clinchemed@aacc.org. 
References: 
1 Moher D, Schulz KF, Altman DG for the CONSORT Group. The 
CONSORT statement: revised recommendations for 
improving the quality of reports of parallel group randomized 
trials. www.consort-statement.org. 
 
MINIMUM INFORMATION ABOUT A MICROARRAY 
EXPERIMENT (MIAME) 
The MIAME Checklist can be found at 
http://fged.org/projects/miame/. 
MIAME describes the minimum information about a microarray 
experiment that is needed to enable interpretation of the results of 
the experiment unambiguously and potentially to reproduce the 
experiment. 
The MIAME checklist is a description of MIAME principles 
designed to help authors, reviewers, and editors of scientific 
journals meet MIAME requirements and to make microarray data 
available to the community in a useful way. 
MIAME is neither a dogma nor a legal document - it assumes a 
cooperative data provider and a fair reviewer. 
 
MINIMUM INFORMATION ABOUT QUANTITATIVE REAL-TIME 
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PCR EXPERIMENTS (MIQE) 
MIQE Checklist [PDF] 
For studies that include quantitative real-time PCR experiments, 
complete the MIQE checklist for evaluation of qPCR experiments 
during electronic submission. Do not send the checklist via e-mail 
or upload it as supplemental material. The full text of the MIQE 
guidelines is available online: 
http://www.clinchem.org/cgi/content/short/55/4/611. A PDF version 
for all essential components of the checklist can be obtained by the 
link above. 
Recommended nomenclature should be used, including: 
• qPCR for quantitative real-time PCR 
• RT-qPCR for reverse transcription quantitative real-time PCR 
• reference genes instead of housekeeping genes 
• hydrolysis probes instead of TaqMan® probes 
• dual hybridization probes for HybProbes® (LightCycler®) 
probes 
• quantification instead of quantitation 
• Cq instead of Ct, Cp, or TOP 
• quantification cycle instead of threshold cycle or crossing point 
Authors are also encouraged, but not required, to include the 
additional desirable items of the MIQE guidelines (1). The MIQE 
guidelines are intended to help authors plan, perform and present 
qPCR experiments. They are also a guide for reviewers and 
editors to judge the quality of qPCR data. Incomplete information 
may be grounds for manuscript rejection. Use of Supplemental 
Data is encouraged as necessary. The most common errors in 
performing and reporting qPCR data include: 
1 Not enough information for others to replicate the experiment, 
including how the nucleic acid was prepared, reverse 
transcribed, and amplified. Primer sequences are required. 
Probe sequences are strongly encouraged especially in 
methods manuscripts, but their omission may be acceptable 
in clinical manuscripts if they are commercially available as 
products. 
2 Inadequate storage and/or nucleic acid preparation, leading to 
poor nucleic acid quality and variable results. 
3 Suboptimal primers for reverse transcription and/or PCR 
resulting in low yield, specificity and/or PCR efficiency. 
4 Inappropriate analysis of data. 
5 Use of a single reference gene in RT-qPCR without justification 
(2). 
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The guidelines require not only delineation of what was done, but 
presentation of evidence that validates the method used. For 
example, these include evidence of RNA integrity and purity, PCR 
specificity, calibration curves and calculations of PCR efficiency 
and limits of detection. At the option of the editor, MIQE 
requirements may be relaxed in reports using qPCR arrays, 
although all manuscripts will be judged on their relative merit, and 
the relative merit of a manuscript using qPCR increases as 
compliance with the MIQE guidelines increases. 
References: 
1 Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista 
M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, 
Vandesompele J, Wittwer CT. The MIQE guidelines: 
minimum information for publication of quantitative real-time 
PCR experiments. Clin Chem. 2009 Apr;55(4):611-22. 
2 Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, 
De Paepe A, Speleman F. Accurate normalization of real-
time quantitative RT-PCR data by geometric averaging of 
multiple internal control genes. Genome Biol. 2002 Jun 
18;3(7):RESEARCH0034. 
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ETHICAL CONSIDERATIONS 
In order to ensure the highest ethical standards, Clinical Chemistry 
adheres to the recommendations from the International Committee 
of Medical Journal Editors (ICMJE) and the Committee on 
Publication Ethics (COPE) for guidance on policies and procedures 
regarding scientific misconduct. Misconduct including, but not 
limited to, the following is strictly prohibited and will result in 
immediate removal of a paper from consideration by the journal. 
Duplicate Submissions 
Submissions that are under review or that have been previously 
published with another journal. 
Duplicate Publications and Plagiarism 
Manuscripts that have substantial overlap with a manuscript that 
has already been published, without proper citation. 
Back to Top 
 
TYPES OF SUBMISSIONS 
• Article 
• Citation Classic 
• Clinical Chemist 










• Genetic Metabolic 
Series 
• Inspiring Minds 






• Special Report 
• Unveiling the Right Side 
• What Is Your Guess? 
 
ARTICLE 
Research or scientific articles are submitted directly from authors. 
There are no restrictions on topics that are considered for 
publication, as long as the subject matter is original and relates 
experimentally or theoretically to the field of laboratory medicine. 
The information must be sufficiently detailed not only to enable 
readers to understand and appreciate the material presented, but 
also to permit replication of the work by other scientists in the field. 
Articles should contain a structured abstract limited to 250 words 
and formatted to include separate headings of: Background, 
Methods, Results, and Conclusions. The main text should not 
exceed 3,500 words. The manuscript should have no more than 40 
references and a total of 6 tables and/or figures. Supplemental 
data are permitted for Articles. 
Articles should list no more than 20 authors, with any additional 
contributors listed in the Acknowledgments. Although exceptions 
are rare, you may email clinchemed@aacc.org detailing each 
author's contribution to your submission, which will be forwarded to 
the editor. 
 
Authors may submit short videos to complement their Articles. 
Videos can be used to illustrate a laboratory technique, hardware 
prototype, or clinical presentation that would benefit from such an 
addition, or to visually communicate to the reader novel features, 
special steps in a procedure, pitfalls, or other information that may 
not be easily conveyed through text or a figure. Videos should be 
of high quality, no more than 5 minutes in length, and submitted as 
.mp4 files. Please do not send proprietary file types such as .wmv 
(Windows Media) and .rm (Real Media) files. 
 
Authors of Articles will be prompted at submission to provide a 
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brief summary of their work, not to exceed 100 words. In the event 
of acceptance, this will be recorded and included as an audio file in 
all online versions of the table of contents. The Audio Summary 
should address the following questions: 
  
1 What was the paper about/what was the rationale for the study? 
2 How did you approach the problem? 
3 What were your findings? 
4 What are the implications of the findings and how do they add to 
the field? 
A simple phonetic spelling of the first author’s full name should 
also be provided. 
 
CITATION CLASSIC 
Citation Classics are typically invited submissions that highlight a 
landmark article in the field of clinical chemistry. In this feature, one 
of the authors of the original article provides some historical 
insights and anecdotal stories surrounding its publication. 
Citation Classics should not include an abstract and are limited to 
600 words, no more than 6 references, and no more than 5 
authors. Generally, tables and figures are not permitted; however, 
if the text does not exceed 500 words, one table or figure will be 




This monthly feature provides a forum for informing readers about 
general items of interest. Topics might include announcements for 
upcoming conferences, awards received by members of the 
AACC, announcements of new features in the journal, humorous 
items, artwork or photographs from readers, or general scientific 
news. Readers may submit items for consideration in the following 
categories: Unveiling the Right Side, What Is Your Guess?, and 
Genetic Metabolic Series, following the specific guidelines for 
each. The editors will make the final decision on the 
appropriateness and priority for inclusion in this section of the 
journal. 
Please note that the journal is not currently considering unsolicited 
submissions to the Technology Corner, Science in the Arts, and 
Best of Clinical Chemistry sections. 
 
CLINICAL CASE STUDY / COMMENTARY 
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Clinical Case Studies are submitted directly from authors. These 
articles are intended to be educational, with the goal of helping to 
develop or improve problem-solving skills. Clinical Case Studies 
may report unusual (although not necessarily rare) biochemical 
manifestations of disease, atypical presentation of disease, 
situations where the laboratory helped in making or clarifying a 
diagnosis, or information that would be helpful in understanding the 
pathophysiology of a disease. 
Two accompanying commentaries will introduce additional 
concepts that may be useful to readers, discuss confounding 
factors that might affect a diagnosis or analytical result, and/or 
provide comments about the case itself. Commentaries are invited 
and authored by clinical chemists, physicians, or scientists with 
expertise in the area. 
A Clinical Case Study should not include an abstract. It should, 
however, include a case description followed by the case 
discussion, limited to 1,500 words total. References are limited to 
10, and the tables and figures are limited to 2 in total. Authors 
should include 3-5 brief questions regarding the case that would 
stimulate discussion and learning about the disease state. These 
questions will be circulated to educational centers before 
publication. The author should also list up to 5 points to remember 
at the end of the manuscript. The questions and points are not 
included in the manuscript count of 1,500 words. The case should 
read as a bit of a mystery or diagnostic dilemma. The case title, 
case description, and questions should not disclose the diagnosis. 
Supplemental data are not permitted for Clinical Case Studies. No 
more than 5 authors should be listed. 
Commentaries are limited to 300 words. They should not include 
an abstract, references, or tables and figures and should have no 




Corrections are unique and will be considered on a case-by-case 
basis. Authors are encouraged to contact the Editorial Office at 
clinchemed@aacc.org should they wish to submit a Correction or 
should they find a printer error that needs correcting. 
 
EDITORIAL 
These are typically invited submissions. Editorials provide opinions 
and observations by an expert in the field about the subject matter 
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or content of a scientific paper published in Clinical Chemistry. In 
addition to further educating readers on a selected topic, Editorials 
are designed to stimulate readers to formulate their own opinions 
about a paper and its value to the field. In some cases, Editorials 
may also be independent opinions and observations about a 
controversial topic or changes taking place in the field. 
Editorials are limited to 1,500 words. They should not include an 
abstract. References are limited to 15, and tables and figures are 
not permitted. No more than 5 authors should be listed. 
Supplemental data are not permitted for Editorials. 
 
GENETIC METABOLIC SERIES 
The Genetic Metabolic Series falls under the Clinical Chemist and 
contains short clinical cases in biochemical genetics. Each article 
will include the actual case presentation, a chromatogram, the 
biochemical pathway of the defect, and a short case discussion. 
Submissions should not exceed 600 words in length and should 
include no more than 2 tables or figures and 1 reference. 
 
INSPIRING MINDS 
These biographical articles are commissioned to present the 
achievements of distinguished clinical chemists, as well as their 
philosophical views on their professional life and the field of clinical 
chemistry. 
 
LETTER TO THE EDITOR / REPLY 
Letters are submitted directly from authors and can be used to 
report an observation or to discuss a previously published original 
Article. Letters in response to papers other than Articles will not be 
considered for publication. Letters report observations on 
interferences, suggestions to improve test performance, or other 
observations that are of importance to the wider audience. A Reply 
to a Letter may also be solicited by the editors. The one figure or 
table provided should be concise and should not be multipart (i.e., 
Fig. 1A, 1B, 1C, Part 1, Part 2). 
A Letter to the Editor is limited to 750 words. It should not include 
an abstract. The references are limited to 5, and only 1 table or 
figure is permitted. Supplemental data are not permitted for Letters 
to the Editor. 
A Reply is limited to 750 words. It should not include an abstract. 
The references are limited to 5, and only 1 table or figure is 
permitted. Supplemental data are not permitted for Replies. 
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Letters to the Editor and Replies should list no more than 8 
authors, with any additional contributors listed in the 
Acknowledgments. Although exceptions are rare, you may email 
clinchemed@aacc.org detailing each author's contribution to your 
submission, which will be forwarded to the editor. 
In some instances, editors may request that a submission of 
another article type to Clinical Chemistry be decreased to meet the 
requirements of a Letter to the Editor. 
 
MINI-REVIEW 
Mini-Review articles are typically invited submissions. Mini-
Reviews are intended to provide a general overview of a topic. 
Basic information is provided, along with selected references that 
can aid the reader in obtaining additional information about the 
subject. The use of illustrative figures or tables is encouraged. 
A Mini-Review article should consist of a structured abstract limited 
to 250 words with headings of Background, Content, and 
Summary. The text should not exceed 3,500 words. The 
manuscript should have no more than 40 references and a total of 
4 tables and/or figures. Supplemental data are permitted for Mini-
Review articles. 
 
Mini-Reviews should list no more than 5 authors, with any 
additional contributors listed in the Acknowledgments. Although 
exceptions are rare, you may email clinchemed@aacc.org 
detailing each author's contribution to your submission, which will 
be forwarded to the editor. 
 
OBITUARY 
Obituary announcements and associated biographies can be 
commissioned by the Journal or submitted by authors. Prior to 
submission of an Obituary, authors should contact the Journal with 
information about the person who has passed away and with a 
description of the individual’s career achievements and unique 
contributions. A decision will then be made on proceeding with the 
Obituary. 
Obituaries should include personal information about the deceased 
(birthplace, education, place of residence, employment), highlights 
of this person’s achievements (research accomplishments, 
awards, elected positions, committees, service to the profession), 
and anecdotal information about what made the person unique. 
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Obituaries are limited to 600 words with no abstract, references, or 
tables. One figure/image file is permitted. Supplemental data are 
not permitted for Obituaries. 
 
OPINION 
Opinion articles are invited submissions that present the belief or 
personal view of the author(s) on a specific topic. An opinion 
implies a conclusion thought out yet open to dispute. Opinion 
articles are often a formal expression by an expert of his/her 
judgment or advice. Unlike Editorials and Letters to the Editor, 
Opinion articles do not comment on, or refer to, specific papers 
published in the journal. 
An Opinion should not include an abstract and is limited to 1,500 
words, 15 references, 1 table or figure, and no more than 5 
authors. Supplemental data are not permitted for Opinions. 
 
PERSPECTIVE 
These articles are invited submissions. Perspectives highlight a 
clinical, analytical, or basic science report that was published in a 
journal other than Clinical Chemistry but has implications for the 
practice of clinical chemistry. 
Perspectives should not include an abstract. They are limited to 
1,500 words, 5 references, 1 table or figure, and no more than 5 
authors. Supplemental data are not permitted for Perspectives. 
 
POINT/COUNTERPOINT 
These articles are typically invited submissions from experts in a 
selected discipline and provide different viewpoints on a topic that 
may be controversial, lacks consensus in the scientific community, 
or may be of high public interest. In most cases an author or group 
of authors is asked to write the first half of the article, describing 
the importance of the topic, challenges to be addressed, current 
limitations, and/or unmet needs. A second author or group of 
authors is invited to provide a “Counterpoint” discussion of a 
different viewpoint or critical factors. 
Point/Counterpoint submissions should not include an abstract. 
The manuscript is limited to 1,500 words, 15 references, and 1 




This invited feature is meant to highlight a timely and important 
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issue, either clinical or analytical, through a series of questions 
posed to leaders in the field by a moderator. The moderator is 
required to include an introductory paragraph and photographs of 
each expert. Five to 8 questions may be posed to 3 to 5 experts 
with the moderator documenting the answers. Submissions are 
limited to 3,500 words. 
 
REFLECTION 
These articles are invited submissions. Reflections are authored by 
highly accomplished scientists in their field who have greatly 
contributed to science. Reflections will be reserved for special 
issues and will focus on the specific advancements the individual 
has made in his or her field. 
Reflections are limited to 2,000 words and should not include an 
abstract. The references are limited to 20, and 1 table or figure is 
permitted. Supplemental data are not permitted for Reflections. 
 
REVIEW 
Review articles are typically invited submissions. Reviews are 
intended to provide comprehensive coverage of a topic, including 
background clinical or analytical information, the relevance and 
importance of the subject matter, and potential future directions. 
The use of illustrative figures or tables is encouraged. 
A Review article should consist of a structured abstract with 
headings of Background, Content, and Summary limited to 250 
words. The text should not exceed 5,000 words. The manuscript 
should have no more than 75 references and a total of 6 tables 
and/or figures. Supplemental data are permitted for Review 
articles. 
 
Reviews should list no more than 15 authors, with any additional 
contributors listed in the Acknowledgments. Although exceptions 
are rare, you may email clinchemed@aacc.org detailing each 




Special Reports may be submitted directly by authors or invited by 
the journal. The types of papers that would be considered include 
consensus reports, guideline development, position statements, or 
evidence-based recommendations on test utilization or quality 
specifications. The editors may also decide to classify other 
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miscellaneous submissions under this heading. 
A Special Report should consist of a structured or unstructured 
abstract limited to 250 words. The main text should be no more 
than 5,000 words. The manuscript should have no more than 40 
references and a total of 4 tables and/or figures. Supplemental 
data are permitted for Special Reports. 
 
Special Reports should list no more than 20 authors, with any 
additional contributors listed in the Acknowledgments. Although 
exceptions are rare, you may email clinchemed@aacc.org 
detailing each author's contribution to your submission, which will 
be forwarded to the editor. 
 
UNVEILING THE RIGHT SIDE 
Submissions should highlight the creative side of someone in the 
field of chemistry. This can be poetry, a short story, photographs, 
or other creative artwork. Submissions are limited to 400 words 
and/or one image, photograph, or poem. All submissions are 
subject to review. Cover letter should state interest in contributing 
to Unveiling the Right Side and must be submitted under the 
category of Clinical Chemist. 
 
WHAT IS YOUR GUESS? 
Submissions for this 1-page quiz should consist of an image or lab 
values, a case description (less than 75 words), 3 questions, case 
discussion (less than 75 words), and no more than 5 references. 
Cover letter should state interest in contributing to What Is Your 
Guess? and must be submitted under the category of Clinical 
Chemist. 
What Is Your Guess? submissions should list no more than 5 
authors. Although exceptions are rare, you may email 
clinchemed@aacc.org detailing each author's contribution to your 
submission, which will be forwarded to the editor. 
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MANUSCRIPT PREPARATION 
• Author Contribution Requirements 
• Manuscript Guidelines 
• Submission/Publication Fees 
• Journal Categories 








• Figure Captions 
• Figures 
• Color 
• Supplemental Data 
 
AUTHOR CONTRIBUTION REQUIREMENTS 
Clinical Chemistry follows the recommendations for authorship set 
out by The International Committee of Medical Journal Editors 
(ICMJE). In accordance with these recommendations, manuscripts 
are considered for publication with the understanding that each 
listed author must meet the following criteria: 
1 Substantial contributions to the conception or design of the 
work; or the acquisition, analysis, or interpretation of 
data for the work; AND 
2 Drafting the work or revising it critically for important 
intellectual content; AND 
3 Final approval of the version to be published; AND 
4 Agreement to be accountable for all aspects of the work in 
ensuring that questions related to the accuracy or 
integrity of any part of the work are appropriately 
investigated and resolved. 
Any change in authors and/or contributors after initial submission 
must be approved by all authors. This applies to additions, 
deletions, change of order to the authors, or contributions being 
attributed differently. If a change is made to the author list after 
submission or during any revision, the submitting author must send 
an e-mail to clinchemed@aacc.org explaining the reason for the 
change and copying all authors for their approval. Any additions or 
deletions must be made in the electronic submission record as well 
as on the manuscript itself. At revision, be sure to select "Yes, the 
authorship has changed" when prompted. 
Author limits may be imposed for certain submission types. Please 
review the specific requirements for your submission type. Please 
list only the allowed number of authors in the author list, with the 
remaining contributors listed in an Acknowledgment. Exceptions 
may be made at the discretion of the editor. 
Any alterations made to the manuscript after submission must be 
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approved by the editor. Authors may upload the request letter to 
the online submission system as a supplemental file or send the 
letter via e-mail to the Clinical Chemistry editorial office at 
clinchemed@aacc.org. The editor may contact any of the authors 
and/or contributors to ascertain whether they have agreed to any 
alteration. 
1 The International Committee of Medical Journal Editors (ICMJE) 
Uniform Guidelines for Manuscripts Submitted to Biomedical 
Journals (1) specifically state that “all contributors who do not 
meet the criteria for authorship, such as a person who . . . 
provided purely writing assistance" be named in the 
acknowledgments. 
2 Important contributions to an article should be recognized and 
appropriately attributed in that article. 
3 Good medical writers and editors can make valuable 
contributions to the publication process, often improving the 
clarity of the communication, broadening the scope of 
literature review, providing an extra level of data review, 
adding balance and objectivity, and shortening the time 
needed for manuscript development. 
4 The American Medical Writers Association (AMWA) 
http://www.amwa.org believes that these important 
contributions deserve recognition. 
5 Readers benefit from knowing about the involvement of 
professional writers and editors. 
6 Disclosing the editorial contribution and the source of funding of 
the writer and editor allows the reader to make informed 
judgments about the objectivity of the article. 
7  
8 Note that the AMWA position statement recommends 
acknowledgment of pertinent professional or financial 
relationships as well as acknowledgment of the contributions 
of writers and editors. 
9 It also recommends that the person being acknowledged be 
given the opportunity to grant or refuse permission for the 
acknowledgment. 
References: 
1 International Committee of Medical Journal Editors. Uniform 
requirements for manuscripts submitted to biomedical 





• MS Word document (.doc or .docx) is required for all 
submissions. 
• All figures must be uploaded separately as Image Files in 
Tagged Image File Format (.tiff), Encapsulated Postscript 
(.eps) or PowerPoint (.ppt) with embedded fonts. 
• All submissions must be double-spaced, 1 inch margin, twelve-
point font size in Arial, Helvetica, Times New Roman and 
Symbol font (for non-text characters). 
• All submissions must be page numbered. 
• Do not use headers or footers. 
• Use standard abbreviations and define all nonstandard 
abbreviations. 
• All submissions require a title page. 
• Reporting of Concentration Units: 
1 Analyte concentrations will be expressed in the text in the 
traditional mass unit (mg/dL, ng/ml, and so forth) 
followed by the SI unit in parentheses. Exceptions 
would include those analytes in which SI units are used 
globally, such as electrolytes (use mmol/L for sodium, 
potassium, chloride, and CO2 values), or cases in 
which the traditional unit and the SI unit differ by only a 
factor of 1000 in both the numerator and denominator 
(e.g., ng/mL vs µg/L). In such cases, the unit of 
measure consistent with common practice will be used. 
2 The unit of measure mg/L should be used only when 
referring to SI units or when national or international 
guidelines require or recommend that the concentration 
of an analyte be expressed in that unit of measure, 
such as for high-sensitivity C-reactive protein. The unit 
of measure U/L will be used for most enzyme activites. 
3 Only traditional units will be used for tables and figures in 
the printed version of a report; SI conversion factors 
will be provided in legends. All tables and figures will 
also be presented in SI units. These tables and figures 
will be made available in online supplements to 
published articles and letters. Authors will provide both 
versions before final acceptance of a manuscript. SI 
units are available at Bureau International des Poids et 
Mesures. 
• Supplemental Data are accepted for online publication only and 
are limited by submission types (See Types of Submissions 
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for details). 
• Follow the guidelines for length restrictions, abstract, reference, 
table and figure, and supplemental data limits as outlined in 
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S or U: 250 40 4 Yes 
*Word limit consists of the body of the manuscript only; it does not 
encompass the title page, abstract, acknowledgments, references, 
tables, figure legends, figures, or Clinical Case descriptions, 
questions, and points to remember. 
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**Structured abstracts contain the headings (1) BACKGROUND, 
(2) METHODS, (3) RESULTS, (4) CONCLUSIONS for all 
applicable article types except for Reviews and Mini-Reviews. 
Abstracts for Reviews and Mini-Reviews contain the headings (1) 
BACKGROUND, (2) CONTENT, (3) SUMMARY. 
***If a figure accompanies the paper, the image should not be 
multipart (i.e., Fig. 1A, 1B, 1C, Part 1, Part 2). 
 
SUBMISSION/PUBLICATION FEES 
Authors are not required to pay submission fees in order to submit 
their work to Clinical Chemistry. If color figures are present in the 
submission, authors of accepted papers may be required to pay a 
fee for color printing at the time of publication. 
Authors have the option to request that their papers be made open 
access immediately at the time of online publication, for a fee of 
$3500. For more information or to request open access 
publication, contact the Editorial Office at clinchemed@aacc.org. 




Articles are grouped in the journal according to subject. Upon 
submission, authors are required to select the journal category that 
best describes their manuscript from the list indicated below: 
• Molecular Diagnostics and Genetics (MDG) 
• Evidence-Based Laboratory Medicine and Test Utilization (TUO) 
• Hemostasis and Thrombosis (HAT) 
• Proteomics and Protein Markers (PPM) 
• Cancer Diagnostics 
• Lipids, Lipoproteins, and Cardiovascular Risk Factors (LLP) 
• Drug Monitoring and Toxicology (DMT) 
• Hematology (HEM) 
• Endocrinology and Metabolism (END) 
• Point-of-Care Testing 
• Automation and Analytical Techniques (AAT) 
• Informatics and Statistics 
• Laboratory Management (LMA) 
• General Clinical Chemistry (GCC) 
• Animal Clinical Chemistry (ANI) 
• Clinical Immunology (CLI) 
• Pediatric Clinical Chemistry (PED) 
• Nutrition (NUT) 
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• Infectious Disease 
• Other Areas of Clinical Chemistry (OTH) 
 
TITLE PAGE 
The first page of the manuscript should include the following 
information: 
1 full title of submission, which should include only generic, not 
trade, names when describing a test, assay, etc.; 
2 running head of fewer than 50 characters (including spaces); 
3 list of all authors (first name, middle initial, and last name, in that 
order); 
4 names of each author’s institution and an indication of each 
author’s affiliation; 
5 name, address, telephone and fax number, and e-mail address 
of the corresponding author; 
6 keywords; 
7 any previous presentation of the manuscript; 
8 list of abbreviations, in order cited; and 
9 list of any “Human Genes" discussed in the paper. For each 
gene, indicate the gene symbol and gene name approved by 
the HUGO Gene Nomenclature Committee. Include other 
name(s) that are used in the paper or are widely used in the 
literature for the gene. 
 
ABSTRACT (STRUCTURED AND UNSTRUCTURED) 
Structured abstracts should be formatted to include separate 
headings of: Background, Methods, Results, and Conclusions. For 
Mini-Review and Review articles the headings should be: 
Background, Content, and Summary. Both structured and 
unstructured abstracts are subject to a limit of 250 words. 
Unstructured abstracts do not require separate headings. 
Citation Classics, Clinical Case Study, Commentary, Editorial, 
Inspiring Minds, Letters to the Editor, Reply, Obituary, Opinion, 
Perspective, and Point/Counterpoint submissions do not require an 
abstract. 
In addition to appearing at the beginning of the manuscript, 
abstracts must be uploaded to the abstract field of the Manuscript 
Metadata page online upon submission. 
 
TEXT 
The body of the manuscript should be written as concisely as 
possible and must not exceed the manuscript category word limits 
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described herein. All pages must be double-spaced and all lines 
numbered. The body of the paper should include: Introduction, 
Materials and Methods, Results and Discussion. 
• Introduction - why was the study undertaken? 
• Materials and Methods - how was the study done? 
• Results - what did the study find? 
• Discussion - what might it mean, why does it matter, what next? 
Full corporate names of manufacturers of materials should be 
utilized (omit Inc., Co., GmbH and similar words). After the first 
mention, use a shorter name (e.g., for Bio-Rad Laboratories, use 
Bio-Rad). Only the manufacturer’s name should be used, unless 
the item in question was a gift, in which case the city, state, and e-
mail or website of the company should be included. 
Reporting of Concentration Units: Analyte concentrations will be 
expressed in the text in the traditional mass unit (mg/dL, ng/ml, 
and so forth) followed by the SI unit in parentheses. 
Use of human subjects requires a statement in the text indicating 
whether the procedures followed were approved by your 
institution's responsible committee or were in accordance with the 
current revision of the Helsinki Declaration and whether subjects 
gave informed consent. 
Accession numbers for data sets or sequence reads that have 
been deposited in a public database should be provided in the 
Materials and Methods section of the text. 
Where applicable, a ClinicalTrials.gov identifier for a registered 
clinical study should be listed both at the end of the abstract and at 
the first mention of the trial acronym in the main text. 
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disclosure form is electronic and completed during the submission 
process within the Bench>Press submission system. Disclosures 
should not be included in an Acknowledgment or elsewhere within 
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provided, you will not be able to access the disclosures. After 
registration, the system may take up to 15 minutes to refresh 
before the disclosure form appears. 
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companies or proprietary entities producing scientific services, 
which have an investment, licensing, or other commercial interest 
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“References” with no additional punctuation. In-text citations 
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• Italic or boldface type is prohibited in the referenced citations. 
• List and number the references in the order that they appear in 
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• Do not use the MS Word document numbering tool. Number 
each reference manually with the numeral and a period, 
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• Authors’ names are inverted (last name, first/second initial). Do 
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Tables are considered text. They should appear embedded as part 
of the submission directly following the reference section. Each 
table should appear on an individual page. Manuscripts will be 
returned to authors if the tables are uploaded as separate table 
files. (Manuscripts will not be returned for this reason if tables have 
been uploaded as supplemental data or if they are to be 
considered figures, in the special circumstances described below.) 
Each table should be clearly labeled and numbered consecutively 
with Arabic numerals (Table 1, Table 2, etc.). The abbreviations 
used must be defined. As with the text, reporting of concentration 
units consists of analyte concentrations expressed in the text in the 
traditional mass unit (mg/dL, ng/ml, and so forth) followed by the SI 
unit in parentheses. 
Tables should not be divided into parts. Separate parts (Table 1A, 
Table 1B, etc.) will be considered separate tables and will count 
toward your overall table/figure count. 
Table captions should be limited to 60 words. 
Each column of an individual table must have a heading and be 
clearly defined. Indicate explanatory footnotes with superscript 
lowercase italic letters in alphabetical order. 
Tables will be converted into a standard format for publication that 
will not include color. Large or complex tables or tables that include 
graphic elements should be submitted as figures or as 
supplemental data for online publication only. The Editor may 
choose to make any table supplemental as he/she deems 
necessary. 
If a table has been published previously, acknowledge the original 
source in the table caption. You must obtain written permission 
from the copyright holder to reproduce the table and upload this 
permission as supplemental data. Please specify whether the table 
has been exactly reproduced or adapted from the original source, 
and provide a copy of the original table if it has been adapted. 
Even if the table has been modified, it may still require a 
permission. Any costs associated with table permissions will be 
borne by the author. Contact the editorial office at 





Figure captions and sub-captions must be listed together on an 
individual page directly following the tables or the references if the 
submission does not include tables. Each figure requires a figure 
caption and should be clearly labeled (Figure 1, Figure 2, etc.). 
Multi-panel figures and figures with parts (a, b, c, etc.), should be 
distinctively labeled (Figure 1A, Figure 1B, Figure 2A, etc.). 
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If a figure has been published previously, acknowledge the original 
source in the figure caption. You must obtain written permission 
from the copyright holder to reproduce the figure and upload this 
permission as supplemental data. Please specify whether the 
figure has been exactly reproduced or adapted from the original 
source, and provide a copy of the original figure if it has been 
adapted. Even if the figure has been modified, it may still require a 
permission. Any costs associated with figure permissions will be 
borne by the author. Contact the editorial office at 




All figures must be uploaded separately as image files in Tagged 
Image File Format (.TIFF) or Encapsulated Postscript (.EPS). 
Microsoft Power Point (.PPT) is also acceptable; however, the 
graphics must contain embedded fonts with one image per slide, 
one slide per file. Each image should have a resolution of 600 
dots-per-inch (dpi). More detailed specifications can be found on 
our print publication vendor’s page at CADMUS Digital Art Support. 
The submission system is designed to retrieve the manuscript file 
and separate image file(s) and combine or merge the files into an 
individual Portable Document Format (.PDF) for reviewing 
purposes. It is the responsibility of the author to verify the quality of 
the image file(s) after the conversion to PDF. It may be necessary 
to alter the individual image file(s) to ensure the content is not lost 
or misconstrued in the merged PDF. 
Submissions will be returned to authors if the figures are 
embedded within the manuscript file and not uploaded separately 
or if the figures have become illegible in the merged PDF. 
Do not place unnecessary graphics, such as borders, in or around 
your figure. Pay particular attention to the quality of the lines, 
symbols, and patterns. Published figures are reduced to 1 column 
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symbols or lettering are not clear, you will need to increase the font 
size. Letters should be 8-10 points when reduced, and subscripts 
no less than 6 points. Initial capitals and lower case letters and a 
medium (not bold) sans serif font are required. European PI, 
Helvetica, Mathematical PI, Times Roman, and Symbol fonts are 
Type 1 PostScript fonts supported by our printer for the creation of 
digital art figures. 
The x-axis and y-axis should be clearly labeled, and the units of 
measurements given. This includes using decimal points instead of 




The costs of publishing color illustrations in print will be borne by 
the author. Costs are $1500 for the first figure and $500 for each 
subsequent figure, or parts of figures. Upon acceptance, authors 
will be billed for the color costs unless a request to print figures in 
black and white is received via cover letter or e-mail. Color 
versions of figures may be provided for publication in the online 
Journal at no extra charge. Please note your color preference 
and/or your agreement to pay for color printing in your cover letter. 
If black and white printing is requested, color figures alone should 
still be submitted to the Journal. The figures will be converted to 
grayscale by the printer. Authors should not attempt to convert the 
figures or submit both color and grayscale versions. 
 
SUPPLEMENTAL DATA 
Figures or tables too large for print, manuscript material that 
exceeds the limitation for the specific submission type, or 
appendices should be submitted for online publication only. These 
files should be marked and uploaded separately as supplemental 
files during submission and should be referenced within the text as 
supplemental data (i.e., "See Supplemental Table 1", "See 
Supplemental Figure 1", etc.). Supplemental files must be labeled 
consecutively (i.e., Supplemental Table 1, Supplemental Table 2, 
Supplemental Figure 1, Supplemental Figure 2, etc.). 
When labeling your files and referencing them within the main text, 
please keep in mind the preferred naming conventions for 
supplements. “Supplemental” is preferred over “Supplementary,” 
and the word “Data” is not necessary in table or figure titles (i.e., 
“Supplemental Table 1,” not “Supplemental Data Table 1” or 
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contained in a single file, that file should be referred to as 
"Supplemental Data." 
Captions for the supplemental data should be uploaded as a 
separate supplemental file or embedded within the supplemental 
data/table/figure file. Do not include the supplemental captions in 
your manuscript file. 
Please be advised, supplemental data are permitted for Article, 
Inspiring Minds, Mini-Review, Review, and Special Report 
submissions only. Manuscripts of all other types with supplemental 
data will be returned to authors. 
Supplemental data will be reviewed as part of the manuscript and 
will be evaluated for its importance and relevance; however, it 
should not appear in the “Peer-reviewed PDF” file created by the 
submission system. 
If accepted and posted online, the supplemental data will be 
referenced in the text of the print article directing readers to the 
URL of the website. 
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WHAT IS BENCH>PRESS? 
Clinical Chemistry uses the Bench>Press™ (B>P) manuscript 
submission, tracking, review, and publishing system, developed by 
Stanford University Libraries' HighWire Press. 
B>P is an Internet application and operates with standard 
browsers, although a JavaScript-enabled browser (such as Internet 
Explorer) is recommended. 
For user convenience and accessibility, B>P converts uploaded 
manuscript files to Adobe Portable Document Format (PDF). 
Adobe Acrobat Reader is required to view these files and is 
available at no cost. Click the following link to download: 
http://www.adobe.com/products/acrobat/readstep2.html 
B>P uses a series of pages, presented one at a time, to guide the 
author through the submission process. For help during regular 





Please see FAQs at 
http://submit.clinchem.org/journals/clinchem/forms/registration_faq.
pdf for more extensive help. 
Before submitting a manuscript or review of a manuscript, you 
must register with our manuscript submission and tracking system. 
Register at http://submit.clinchem.org/cgi/registration. 
After accessing the registration page, you will need to verify your 
e-mail address. If there is an existing account with an old e-mail 
address, do not create a new account with a different e-mail 
address. Simply access the account with the out-of-date e-mail 
address, and use the system to update/change your e-mail 
address. 
Always use the same e-mail when accessing the system. Multiple 
e-mail addresses will cause repeated registrations and the creation 
of multiple accounts, which could lead to future system access 
problems. 
NOTE: If you have used other Bench>Press journals, you must 
use the same e-mail address and password to register with Clinical 
Chemistry. Although all Bench>Press journals require the same e-
mail address and password for access, this is the only shared 
information. You must be registered individually with each journal 
you are trying to access. 
 
CHANGING CONTACT INFORMATION AND PASSWORD 
E-mail addresses, passwords, and other contact information can 
be modified at any time by clicking "Personal Info" from the gray 
navigation bar at the top of any page within the manuscript 
processing system. 
Feel free to contact the Editorial Office via e-mail at 
clinchemed@aacc.org should you need assistance. 
 
TROUBLESHOOTING 
Please see FAQs at 
http://submit.clinchem.org/submission/submissionhelp for more 
extensive help. 
Trouble Registering 
All authors and reviewers must be registered with Clinical 
Chemistry. To register, go to http://submit.clinchem.org, and click 
the “Create a New Account” button to the left of the login screen. If 
you do not receive a request to create a password and answer a 
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security question, you are most likely registered with Clinical 
Chemistry or another Bench>Press journal. Clinical Chemistry 
uses an online manuscript management system called 
Bench>Press. Bench>Press is used by hundreds of journals, all of 
which share the same registration system. If you have already 
registered with another Bench>Press journal, you do not need to 
repeat the registration process. You simply need to sign in with the 
same e-mail and password and complete a profile page for Clinical 
Chemistry. 
 
If you can't remember with which journal(s) you registered, this 
information can be sent by clicking the "Send My Registration 
Details" button on the registration page. 
 
No e-mail response after registering: 
If you have registered and have not received a verification e-mail, 
this may be due to a spam blocking filter associated with your 
institutional server. You may need to manually register 
clinchemed@aacc.org so as to accept mail from Clinical 
Chemistry. Your Systems Manager should be able to help you with 
this problem. 
Java Difficulties: 
If you are using Internet Explorer as your browser and are having 











You may check to see if the site works properly by going to 
http://submit.clinchem.org/. 
Please note that login information (e-mail and password) for the 
submission and review site will not be the same login information 
you use if you subscribe to the online journal. 
Duplicate Accounts: 
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Often, due to problems with the initial registration or infrequent 
use, an author may have two accounts listed. Multiple accounts 
lead to future system access problems and therefore must be 
merged. 
If an author or reviewer suspects this is the problem, send a 
request with the preferred e-mail address, current contact 
information, and the suspected invalid e-mail address to the 
Clinical Chemistry editorial office at clinchemed@aacc.org. 
Cookies preventing login: 
Bench>Press requires users to have their browser set to accept 
cookies in order to maintain their logged-in status throughout the 
system. A "cookie" is a message given to a browser by a server. 
The browser stores the message, and the message is sent back to 
the server each time the browser requests a page from the server. 
If the user does not have cookies enabled, the user will be required 
to repeatedly sign in to the system. 
Most browsers will allow the user to manually alter the cookie 
settings from the Tools or Internet Options bar. 
Expertise Terms: 
The Area of Expertise list was developed to help editors choose 
reviewers who possess specific knowledge in a given area. 
Our tracking system has been set to allow this page to appear---as 
a gentle reminder---until the reviewer has selected at least one 
item on the list. As soon as the reviewer selects a topic and saves 
it, it will no longer appear. 
Changing these areas of expertise or adding more detailed 
information can be accomplished by simply logging into 
http://submit.clinchem.org/ at any time and clicking the Personal 
Info area at the top of the page. 
On the lower right side of the page, the user will find "Expertise 
Terms: Edit Expertise Terms." Click on this link and change the 
data accordingly. 
Conversion Errors: 
Receiving a conversion error means that conversion of your 
manuscript to PDF format has failed. 
Invalid file types are the most common cause of conversion failure. 
Be sure your file names end with extensions appropriate to the file 
type (i.e. ".doc", ".tif" or ".eps"). Mac computers generally leave off 
the file type extension and it must be added manually. 
Formats that are not supported include the following: Bitmap 
(.bmp), PICT (.pict), Excel (.xls - Excel tables can be embedded in 
word processing documents), Photoshop (.psd), Canvas (.cnv) and 
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CorelDRAW (.cdr). Multi-slide PowerPoint files (.ppt). If any of 
these have been used to create your file, you will need to convert 
the file to an acceptable file format for submission in order for the 
files to convert properly. 
Large or numerous files may slow the conversion process of 
submission, sometimes resulting in a system "time out" or 
conversion failure. It may be appropriate to upload and wait for the 
conversion of an individual file before proceeding with the 
remaining files. The Bench>Press submission and tracking system 
has limits of how much data can be uploaded at one time. 
Generally most files become unwieldy when they pass the 1 MB 
(megabyte) mark. 
For reference: 
1000 Bytes (B) = 1 Kilobyte (KB) 
1000 Kilobytes (KB) = 1 Megabyte (MB) 
1000 Megabytes (MB) = 1 Gigabyte (GB) 
Empty HTML references field: 
You may find that your HTML references section is empty. This 
can be remedied by including the heading "References" before the 
references section in your paper. 
HTML references cannot be edited directly; any changes must be 
made by re-uploading your manuscript file during the proofing 
stage. 
In addition, uploading a PDF file as your manuscript source file will 
prevent the references from parsing to the Clinical Chemistry 
HTML reference window. 
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COPYRIGHT 
Upon acceptance, all authors are required to read and sign the 
Copyright Transfer Agreement. Each author will be invited via e-
mail to sign a statement confirming that the manuscript does not 
contain material for which publication would violate any copyright 
or other personal or proprietary right of any person or entity. U.S. 
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registered with our online submission system to access, read, and 
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Manuscripts will be held until all copyrights are received. In the 
event that copyrights are not received, the manuscript will not be 
published. 
Manuscripts will not be prohibited from publication solely on the 
basis of a web-posting of a talk at a medical or scientific meeting 
that presents all or part of the content of the submitted manuscript. 
Authors are expected to retain – for a minimum of 1 year after 
publication – the raw data from laboratory or clinical studies and to 
present these data upon request of the Editor if the data are 
contested. 
Authors are expected to identify to the Editor any other 
manuscripts (in print, accepted, have been submitted, in 
preparation) that relate to the submitted manuscript, especially if 
any patients or results are described in both. 
Questions related to the possibility of perceived redundant 
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